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 ABSTRACT 
Schizophrenia is a complex disorder with symptoms ranging from hallucinations to poor social 
functioning and cognitive deficits. Despite decades of research, the etiology of the disease 
remains puzzling. Genetic aberrations as well as exposure to infection during early life are 
associated with an increased risk for development of the disease. Recent studies also describe 
an immune activation in schizophrenia. The immune-related and neuroactive compound 
kynurenic acid (KYNA), is implicated in the pathophysiology of the disease. KYNA is an 
astrocyte-derived end product of the kynurenine pathway, the main metabolic route of 
tryptophan degradation. The aim of the present thesis was to evaluate if disturbances – genetic 
or caused by early-life infection – in the kynurenine pathway, in particular with regard to 
KYNA, could contribute to the development of neuropsychiatric disorders, such as 
schizophrenia. Our results show that infection with the neurotropic influenza A/WSN/33 virus 
generates a profound induction of the kynurenine pathway in vitro in mouse cell cultures of 
cortical glial cells and hippocampal neurons, including a robust increase of transcripts encoding 
IDO and TDO, the enzymes regulating the first and rate-limiting reaction of KYNA production. 
A systemic injection of the influenza A/WSN/33 virus to wild-type and immune-deficient mice 
(Tap1-/-), that lack CD8+ T cells, at postnatal day (P) 3 or 4 showed that the infection stimulated 
the kynurenine pathway in early life. The Tap1-/- mice showed a more persistent induction of 
the kynurenine pathway enzymes. At P13, infiltration of T cells was observed in the brains of 
infected wild-type mice, accompanied by a transient elevation of brain KYNA, which was also 
observed in the Tap1-/- mice. When investigating the long-term behavioral effects of the 
neonatal infection, we found that Tap1-/-, but not wild-type mice, displayed impaired prepulse 
inhibition (PPI) in adult life. In adult wild-type mice, the neonatal virus infection was 
associated with a potentiated D-amphetamine-induced increase in horizontal activity, a 
behavioral response proposed to reflect schizophrenia. To assess the specific role of brain 
KYNA in the behavioral abnormalities seen following neonatal infection, brain KYNA was 
elevated in wild-type mice at P7-16 by the administration of its immediate precursor L-
kynurenine. Similar to infected Tap1-/- mice, these mice showed a mild disruption in PPI in 
adulthood. Furthermore, these mice showed a tendency of hyper-responsiveness to D-
amphetamine in locomotor activity. These results indicate that induction of the kynurenine 
pathway, involving a transient accumulation of brain KYNA in early life, could contribute to 
behavioral aberrations in adulthood related to schizophrenia. Thus, elevated levels of brain 
KYNA during a critical period in neurodevelopment might offer a molecular basis of infection 
as a risk factor for schizophrenia. Furthermore, this thesis reveals that elevated levels of CSF 
KYNA in human subjects of a Swedish population are associated with a missense single 
nucleotide polymorphism in the KMO gene, rs1053230. This genetic deficit could result in a 
dysfunctional KMO enzyme, thereby shunting kynurenine metabolism to KYNA, in line with 
the increased levels of kynurenine and KYNA observed in patients with schizophrenia. 
 
Altogether, this thesis suggests that an early-life CNS induction and/or a genetic deficit of the 
kynurenine pathway could predispose for development of schizophrenia through the elevation 
of brain KYNA. 
 
 
LIST OF PUBLICATIONS 
I.  Maria Holtze, Linnéa Asp, Lilly Schwieler, Göran Engberg, Håkan Karlsson. 
Induction of the kynurenine pathway by neurotropic influenza A virus 
infection. Journal of Neuroscience Research 2008; 86: 3674-3683 
 
II.  Linnéa Asp, Maria Holtze, Susan B. Powell, Håkan Karlsson, Sophie Erhardt. 
Neonatal infection with neurotropic influenza A virus induces the kynurenine 
pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. 
International Journal of Neuropsychopharmacology 2010; 13: 475-485 
 
III.  Maria Holtze, Susan B. Powell, Linnéa Asp, Håkan Karlsson, Göran Engberg, 
Sophie Erhardt. Behavioral disturbances in the adult mouse following neonatal 
virus infection or neonatal kynurenine treatment – role of brain KYNA. 
Manuscript. 
 
IV.  Maria Holtze, Peter Saetre, Sophie Erhardt, Lilly Schwieler, Thomas Werge, 
Thomas Hansen, Jimmi Nielsen, Srdjan Djurovic, Ingrid Melle, Ole A. 
Andreassen, Håkan Hall, Lars Terenius, Ingrid Agartz, Göran Engberg, Erik G. 
Jönsson, Martin Schalling. Kynurenine 3-monooxygenase (KMO) 
polymorphisms in schizophrenia: an association study. Schizophrenia Research 
2011; 127: 270-272. 
 
V.  Maria Holtze, Peter Saetre, Göran Engberg, Lilly Schwieler, Thomas Werge, 
Ole A. Andreassen, Håkan Hall, Lars Terenius, Ingrid Agartz, Erik G. Jönsson, 
Martin Schalling, Sophie Erhardt. Kynurenine 3-monooxygenase 
polymorphisms: relevance for KYNA synthesis in patients with schizophrenia 
and healthy controls. Journal of Psychiatry & Neuroscience 2011; 36: 100175. 
E-pub ahead of print. DOI: 10.1503/jpn.100175 
 
 
 TABLE OF CONTENTS 
1	   Introduction ................................................................................................................. 1	  
1.1	   Schizophrenia .................................................................................................. 1	  
1.2	   Risk factors for the development of schizophrenia ........................................ 2	  
1.2.1	   Environmental influences ............................................................... 2	  
1.2.2	   Genetic aspects ................................................................................ 8	  
1.3	   The kynurenine pathway ............................................................................... 12	  
1.3.1	   Enzymatic steps ............................................................................. 13	  
1.3.2	   Kynurenine pathway induction following immune activation ..... 15	  
1.3.3	   Physiological significance of the kynurenine pathway ................ 18	  
1.4	   Virus infections and CNS immune responses ............................................... 21	  
1.5	   Hypotheses of schizophrenia pathophysiology ............................................. 24	  
1.5.1	   Dopamine in schizophrenia ........................................................... 24	  
1.5.2	   Glutamate in schizophrenia ........................................................... 26	  
1.5.3	   The kynurenic acid hypothesis of schizophrenia .......................... 28	  
2	   Aims of the thesis ...................................................................................................... 31	  
3	   Methodological considerations ................................................................................. 32	  
3.1	   Animals .......................................................................................................... 32	  
3.2	   Drugs .............................................................................................................. 33	  
3.3	   Neonatal treatment ......................................................................................... 33	  
3.3.1	   Influenza A/WSN/33 virus infection of mice ............................... 33	  
3.3.2	   L-kynurenine treatment of mice .................................................... 34	  
3.4	   Influenza A/WSN/33 virus infection of primary cell cultures ..................... 34	  
3.5	   High-performance liquid chromatography ................................................... 35	  
3.6	   Immunofluorescent labeling of T cells ......................................................... 36	  
3.7	   RNA isolation and real-time PCR ................................................................. 36	  
3.8	   Behavioral tests .............................................................................................. 38	  
3.8.1	   Prepulse inhibition ......................................................................... 38	  
3.8.2	   Open field locomotor activity ....................................................... 40	  
3.9	   Human samples ............................................................................................. 41	  
3.10	   Genotyping of human DNA samples .......................................................... 41	  
4	   Results and discussion ............................................................................................... 43	  
4.1	   Influenza virus infection of mice in vitro and in vivo: Induction of the 
kynurenine pathway ................................................................................................ 43	  
4.1.1	   Effects of the virus infection in mouse brain cell cultures ........... 43	  
4.1.2	   Early-life effects of neonatal virus infection in wild-type and 
Tap1-/- mouse brain .................................................................................... 46	  
4.1.3	   Behavioral effects in adult mice following neonatal treatment .... 52	  
4.2	   Human Genetic studies .................................................................................. 59	  
5	   General Discussion .................................................................................................... 64	  
6	   Acknowledgements ................................................................................................... 70	  
7	   References ................................................................................................................. 73	  
 
LIST OF ABBREVIATIONS 
ACMSD 
ALS 
AMPA 
ANOVA 
ATP 
α7nACh 
BBB 
BDV 
CNS 
CNV 
COX 
CSF 
Ct 
DSM 
e.g. 
GABA 
GAPDH 
GPR35 
GWAS 
HAAO 
HIV 
HPLC 
HSV 
ICD 
IDO 
i.e. 
IFN 
IL 
i.p. 
ISI 
 
 
2-amino-3-carboxymuconate-6-semialdehyde decarboxylase 
amyotrophic lateral sclerosis 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionate 
analysis of variance 
adenosine triphosphate 
α7 nicotinic acetylcholine 
blood-brain barrier 
Borna disease virus 
central nervous system 
copy number variation 
cyclooxygenase 
cerebrospinal fluid 
cycle threshold 
Diagnostic and Statistical Manual 
for example (exempli gratia lat.) 
γ-aminobutyric acid 
glyceraldehyde-3-phosphate dehydrogenase 
G protein-coupled receptor 35 
genome-wide association studies 
3-hydroxyanthranilate 3,4-dioxygenase 
human immunodeficiency virus 
high-performance liquid chromatography 
herpes simplex virus 
International Classification of Diseases 
indoleamine-pyrrole 2,3-dioxygenase 
that is (id est lat.) 
interferon 
interleukin 
intraperitoneal 
interstimulus interval  
 
 
 KAT 
Km 
KMO 
KYNA 
KYNU 
LD 
LPS 
MHC 
NAD+ 
NMDA 
P 
PA 
PCP 
PCR 
PPI 
QPRT 
QUIN 
SEM 
SNP 
TAP 
TBE 
TDO 
TLR 
TNF 
3-HK 
3-HAA 
kynurenine aminotransferase 
Michaelis-Menten constant 
kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 
kynurenic acid 
kynureninase 
linkage disequilibrium 
lipopolysaccharide 
major histocompatibility complex 
nicotinamide adenine dinucleotide 
N-methyl-D-aspartate 
Postnatal day 
picolinic acid 
phencyclidine 
polymerase chain reaction 
prepulse inhibition 
quinolinate phosphoribosyltransferase 
quinolinic acid 
standard error of the mean 
single nucleotide polymorphism 
transporter associated with antigen processing 
tick-borne encephalitis 
tryptophan 2,3-dioxygenase 
Toll-like receptors 
tumor necrosis factor 
3-hydroxykynurenine 
3-hydroxyanthranilic acid 
Maria Holtze 
 
 1 
1 INTRODUCTION 
1.1 SCHIZOPHRENIA 
Schizophrenia is a devastating and disabling mental disorder that emerges 
independently of sex, ethnical origin or social/economic status, with a global lifetime 
prevalence estimated to 0.55-0.87% (Goldner et al., 2002; Perälä et al., 2007). The 
disease is commonly characterized by an abnormal reality perception, often with a 
sentiment of lost identity and mental capacity, impairing life dramatically by affecting 
both social and mental functioning.  
 
Schizophrenia develops insidiously and gradually, typically in late adolescence with a 
delay of 3-4 years for females (Hafner, 1998). The disease shows a complex and 
diverse profile, and the symptoms may vary between patients and also within 
individuals over time. The symptoms are generally divided into three broad categories: 
Positive (also denoted as psychotic) symptoms, negative symptoms and cognitive 
dysfunctions (Andreasen, 1995). Positive symptoms refer to those features that are 
additive to normal behavior, including auditory hallucinations and bizarre delusions as 
well as disorganized or monotonic speech. Loss of normal functioning, such as social 
and emotional withdrawal, as well as loss of ambition or will, and a reduced ability to 
experience pleasure are classified as negative symptoms. Cognitive dysfunctions 
include a broad range of features where the patient has difficulties in problem solving 
and abstract thinking. Poor judgment and deficits in attention and memory are also 
examples of cognitive dysfunctions observed in patients with schizophrenia. As a 
uniform guideline for clinicians worldwide, schizophrenia diagnosis can be established 
with either of the two international diagnostic criteria systems: The 4th edition of the 
American Psychiatric Association’s Diagnostic and Statistical Manual of mental 
disorders (DSM-IV) or the 10th International Classification of Disease (ICD-10).  
 
The onset of schizophrenia (typically presented as an acute psychosis) is often preceded 
by non-psychotic premorbid signs of neurological and behavioral problems, reviewed 
in (Jones, 1997). Already during the first years of life, delayed development of speech 
and motor functions (standing, walking etc.) has been observed in children destined to 
develop schizophrenia (Jones et al., 1994; Rosso et al., 2000; Isohanni et al., 2001). 
Introduction 
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Social withdrawal and isolation as well as lower IQ scores have also been reported for 
children that later develop the disease (Aylward et al., 1984; Jones et al., 1994; 
Woodberry et al., 2008). The observations in early life, before the characteristic 
symptoms appear, suggest a neurodevelopmental influence on schizophrenia 
pathogenesis, see (Lewis and Levitt, 2002). Such potential disturbances of brain 
maturation could be a consequence of either genetic or environmental insults, or a 
combination of the two factors. 
 
 
1.2 RISK FACTORS FOR THE DEVELOPMENT OF SCHIZOPHRENIA  
Over the years, a wide range of factors have been suggested to display a specific risk 
for development of schizophrenia. These factors include environmental influences 
throughout the life span, such as Toxoplasma gondii exposure and cannabis use 
(Semple et al., 2005; Yolken et al., 2009), as well as genetic susceptibility to the 
disease. Though these factors are often considered individually, it is not unlikely that 
environmental exposure acts in conjunction with a genetic vulnerability (van Os and 
Kapur, 2009; Owen et al., 2011).  
 
 
1.2.1 Environmental influences  
Substantial evidence from numerous studies, not least those reporting a seasonal 
variation in the number of births of individuals later diagnosed with schizophrenia, 
reviewed in (Torrey et al., 1997), suggests that factors related to fetal, neonatal and/or 
early life environment are involved in the etiology of schizophrenia. In line with this 
view, previous studies have reported an increased risk for the disease that is associated 
with factors such as complications during pregnancy and delivery, exposure to infection 
during early life, migration or ethnical minority status during childhood, or urban 
upbringing. Stress, social adversity or drug abuse, e.g. cannabis, during adolescent or 
early adult life also influences the risk of developing schizophrenia, although these 
factors may be more related to the onset of the disease, reviewed in (Cannon and 
Clarke, 2005; Brown, 2011). Already at the time of the initial description of 
schizophrenia by Kraepelin and Bleuler in the early 1900s, pathological characteristics 
prior to the disease diagnosis were noted. In 1987, a neurodevelopmental hypothesis of 
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schizophrenia was presented in two influential studies (Murray and Lewis, 1987; 
Weinberger, 1987). The hypothesis is based on the observation of structural brain 
changes in patients with schizophrenia, seen already at the onset of the disease, and 
occurrence of premorbid signs at young age in individuals destined to develop 
schizophrenia. Also, the notion that neonatal lesions in the primate brain could result in 
delayed behavioral disturbances contributed to this theory. Thus, disturbances in the 
central nervous system (CNS) during pre- or postnatal life may result in disturbed 
development of the nervous system, for example involving perturbed maturation of 
brain circuits, reviewed in (Lewis and Levitt, 2002). Such disturbances might involve 
exposure to infectious agents in early life.   
 
 
1.2.1.1 Infections in early life 
Infections during pregnancy, induced for example by herpes simplex virus (HSV), 
human immunodeficiency virus-1 (HIV-1), varicella zoster virus or the protozoan 
parasite Toxoplasma gondii can cause neurological sequelae in the offspring (Johnson, 
1994). However, long-term consequences on behavior and cognitive functions may be 
more subtle, without any explicit signs of malformation. The 1957 influenza A2 
pandemic in Finland became an influential target of studies where infection in early life 
was associated with schizophrenia development. It was reported that the offspring of 
mothers who were exposed to influenza virus infection during the second trimester of 
pregnancy had an increased risk of being hospitalized with schizophrenia diagnosis as 
adults (Mednick et al., 1988). However, this study had several limitations as the 
results were based on hospital records, and there were no evidence that the mothers 
were actually infected during this time-point. In a prospective study, maternal 
respiratory infections during the second trimester were also reported to increase the 
risk of schizophrenia spectrum disorders in the offspring (Brown et al., 2000b). These 
data included different infectious agents, indicating that the respiratory infectious risk 
may be wide-ranging, rather than influenza-specific. Some years later, Brown and 
colleagues examined serological data which implied a seven-fold increased risk of 
schizophrenia development in individuals exposed to influenza virus during the first 
trimester of prenatal life (Brown et al., 2004a).  
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Also other neonatal infections have similarly been associated with the later 
development of schizophrenia, reviewed in (Karlsson, 2003; Yolken and Torrey, 
2008). Serological studies report increased levels of HSV type 2 antibodies in mothers 
who gave birth to offspring later developing schizophrenia or other psychotic illnesses 
(Buka et al., 2001a; Buka et al., 2008; Mortensen et al., 2010), and serologically 
documented exposure of rubella virus during fetal life has also been reported to 
increase the risk of non-affective psychosis in adulthood (Brown et al., 2000a). 
Maternal exposure to Toxoplasma gondii additionally appears to be a risk factor for 
schizophrenia. An association between elevated levels of antibodies to Toxoplasma 
gondii in maternal sera and risk of schizophrenia or schizophrenia spectrum disorder 
development in the offspring has been presented, although the result did not reach the 
threshold for statistical significance (Brown et al., 2005). This finding was supported 
by the report of increased Toxoplasma gondii antibody levels in infant blood of 
individuals who later developed schizophrenia (Mortensen et al., 2007). In addition, 
maternal infection with Toxoplasma gondii, as evidenced by increased levels of 
antibodies to the type I strain, was associated with increased risk of psychosis in the 
offspring (Xiao et al., 2009). Moreover, viral or bacterial CNS infections during 
childhood have been suggested to increase the risk for this disease (Koponen et al., 
2004; Abrahao et al., 2005). In a recent epidemiologic study of a Swedish cohort 
including 1.2 million individuals, Dalman and coworkers presented a link between viral 
CNS infections (particularly with mumps virus or cytomegalovirus) during childhood 
and later development of non-affective psychosis (Dalman et al., 2008). Although 
contradicting results also have been presented (Suvisaari et al., 2003; Weiser et al., 
2010), overall, these results indicate an infectious etiology of schizophrenia. 
 
Numerous translational models are utilized to approach a better understanding of the 
etiology and pathophysiology of schizophrenia (Powell, 2010). Several experimental 
studies have suggested that infections in early life have persistent effects, supporting 
the role of the neurodevelopmental hypothesis of schizophrenia. For instance, 
respiratory exposure to a mouse-adapted influenza A virus (NWS/33CHINI) in 
pregnant mice, at gestational day 9, has been shown to cause neuroanatomic 
abnormalities, as well as changes in gene and protein expression, in the developing 
brains of their newborn pups (Fatemi et al., 1998a; Fatemi et al., 1998b; Fatemi et al., 
2002). In adulthood, these mice showed behavioral changes regarding open-field, 
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novel object, and social interaction tests, as well as deficits in sensory motor gating 
(Shi et al., 2003). Furthermore, long-term effects have been observed following 
intranasal infection with another mouse-adapted influenza A virus (WSN/33) in 
pregnant mice at gestational day 14. These effects included changes in gene expression 
in the adult mice brains, but no behavioral changes were observed (Asp et al., 2005). In 
immunodeficient mice, a systemic infection with influenza A/WSN/33 virus on 
postnatal day (P) 3 (thus mimicking the hematogenous route of infection from mother 
to fetus) resulted in a triggered transcriptional activation in the brain as well as 
behavioral changes in adulthood (Asp et al., 2009). 
 
In addition to influenza virus infections, other microbes have also been utilized to 
model the neurodevelopmental theory of schizophrenia by exposure during periods 
corresponding to the late 2nd to early 3rd trimester of human pregnancy. For example, 
subcutaneous injection of the neuroinvasive agent HSV type 1 in neonatal mice pups 
increased hyperactivity in adulthood, concomitant with deficits in learning (Crnic and 
Pizer, 1988). Likewise, neonatal rats intracerebrally inoculated with HSV type 1 
showed deficits in sensorimotor gating in adult life (Engel et al., 2000). Studies using 
Borna disease virus (BDV), a highly neurotropic agent that can induce selective 
damage to the cerebellum, have also been presented. For instance, newborn rat pups 
inoculated intracranially with BDV displayed behavioral abnormalities in adulthood, 
including deficits in sensorimotor gating and in spatial learning and memory, altered 
social interactions, as well as increased hyper-reactivity to aversive stimuli (Pletnikov 
et al., 1999; Rubin et al., 1999; Pletnikov et al., 2002; Lancaster et al., 2007). 
Moreover, impaired sensorimotor gating was observed in adult rats born to dams 
treated with the bacterial endotoxin lipopolysaccharide (LPS) during pregnancy 
(Borrell et al., 2002).  
 
In light of these neonatal infection models, further investigations have focused on 
exposure to cytokines, the modulating molecules which are part of the immune system. 
Subcutaneous administration of various cytokines, such as epidermal growth factor 
(EGF) or interleukin (IL)-1α, to neonatal rodents induces schizophrenia-associated 
behavioral abnormalities during post-pubertal life, including increased rearing activity, 
impaired startle and sensorimotor gating as well as altered social interactions, reviewed 
in (Watanabe et al., 2010). Similarly, a single injection of IL-6 to pregnant mice 
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resulted in behavioral abnormalities, including deficits in prepulse inhibition (PPI, 
reflecting impaired sensorimotor gating) and in latent inhibition (reflecting the ability to 
ignore irrelevant stimuli) in the adult offspring (Smith et al., 2007). Cytokines, 
particularly the IL-6 family, are also suggested to display important functions during 
CNS development (Bauer et al., 2007; Deverman and Patterson, 2009). These 
functions involve for example regulating the self-renewal process of neuroepithelial 
cells, i.e. the precursors of neurons, astrocytes and oligodendrocytes, as well as 
serveing as neurotropic factors, thus promoting cell survival, and as apoptotic 
triggering signals during development. In addition, chemokines (i.e. chemotactic 
cytokines) may serve as migration signals for de novo generated neurons and glial 
cells. Cytokine imbalance during CNS development, for example resulting from an 
early life infection, might thus have crucial consequences for the maturation of the 
brain. Indeed, an excess of pro-inflammatory cytokines in the fetal brain is 
hypothesized to underlie the schizophrenia-related pathology observed 
experimentally following prenatal maternal infections, reviewed in (Meyer et al., 
2009). With regard to this view, it is notable that elevated levels of tumor necrosis 
factor (TNF) and IL-8 in maternal blood has been associated with increased risk of 
psychotic illness or schizophrenia spectrum disorder in the offspring (Buka et al., 
2001b; Brown et al., 2004b). 
 
 
1.2.1.2 NMDA receptor hypofunction in early life 
Disturbance of excitatory transmitter signaling in early life, in particular as regards 
acetylcholine and glutamate, may affect maturation of the brain’s circuitry. Thus, a 
hypofunction of the glutamatergic N-methyl-D-aspartate (NMDA) transmitter system 
during neurodevelopment has been proposed as one potential mechanism in the 
pathogenesis of schizophrenia (Olney and Farber, 1995; Olney et al., 1999; Coyle, 
2006). Neurons are extremely sensitive to disturbances in excitatory transmitter 
signaling during the brain growth spurt period, i.e. the developmental period of 
synaptogenesis, and abnormal inhibition or activation of the NMDA receptor at that 
time triggers neuronal apoptosis or exitotoxic neurodegeneration, respectively (Olney, 
2002). In accordance, a short-lasting pharmacological blockade of the NMDA receptors 
during a few hours in neonatal life has been found to trigger apoptotic 
neurodegeneration in the developing rat brain with the absence of gliosis (Ikonomidou 
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et al., 1999; Young et al., 2005). The developmental period of synapsogenesis initiates 
during the third trimester and spans through the first years of life in humans, whereas in 
rodents the brain growth spurt occurs in the postnatal period, ranging approximately 
from the first day of life to 14 days after birth (Dobbing and Sands, 1979; Rice and 
Barone, 2000). However, this vulnerable period does not only differ between species, 
but also varies between specific brain regions. In accordance with the NMDA receptor 
hypofunction theory, mice that are born with a reduced number of the essential NR1 
subunit of the NMDA receptors display behavioral aberrations similar to those seen in 
pharmacologically induced animal models of schizophrenia (Mohn et al., 1999). 
Furthermore, administration of the NMDA receptor antagonist MK-801 to seven-day-
old rats was associated with impaired sensorimotor gating and increased locomotor 
activity in adulthood (Harris et al., 2003). Similar effects were observed following 
postnatal treatment with the NMDA receptor antagonist phencyclidine (PCP), where 
sensorimotor gating impairments and delayed spatial attention were observed in adult 
rats (Wang et al., 2001). Sub-chronic blockade of the NMDA receptors by increasing 
concentrations of the competitive antagonist CGP 40116 in rats during postnatal life 
has also been shown to provoke a wide range of schizophrenia-associated behaviors 
in adulthood (Wedzony et al., 2008).  
 
Interestingly, kynurenic acid (KYNA), an end product of the kynurenine pathway, is 
the only known endogenous antagonist that blocks both the NMDA and α7 nicotinic 
acetylcholine (α7nACh) receptors. In the late gestational period of rodents, levels of the 
kynurenine pathway metabolites KYNA and 3-hydroxykynurenine (3-HK), as well as 
the pivotal metabolite kynurenine, are reported to be extremely high in the fetal brain. 
After birth, however, the concentration of these metabolites dramatically decreases 
within a few hours. With regard to KYNA, this effect is thought to reflect a standby 
defense mechanism against a possible delivery-related hypoxic-ischemic insult 
(Ceresoli-Borroni and Schwarcz, 2000). However, the effect of an abnormal 
kynurenine pathway induction in the neonatal brain, particularly during the critical 
periods of neurodevelopment, is not well-known. This also motivates elaboration of 
whether a neonatal CNS infection could have an impact on the kynurenine pathway in 
the brain and if this could mediate any long-term effects.  
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1.2.2 Genetic aspects  
Given the large amount of evidence, there is not much doubt that genetic 
vulnerability plays a part in schizophrenia etiology, see (Cardno and Gottesman, 
2000; Cannon et al., 2003). Family history is by far the most established risk factor 
for schizophrenia, and children with both parents affected are estimated to have an 
89% risk of developing the disease (Lichtenstein et al., 2006). In addition, 
monozygotic twins show a much higher concordance rate of schizophrenia 
development than dizygotic twins, with the risk of being affected if the other twin has 
the disease being 30-65% and 0-28% respectively (Cardno and Gottesman, 2000; 
Kringlen, 2000). Despite many years of research, a causal gene for development of the 
disease has not been identified. This has led to speculations such as whether one may 
consider critical genes for different symptoms or other phenotypes (observed 
characteristics) rather than investigating susceptibility genes for schizophrenia per se. It 
is also likely that several gene polymorphisms synergistically influence the generation 
of schizophrenia, possibly also interacting with environmental factors (Harrison and 
Owen, 2003; van Os and Kapur, 2009).  
 
 
1.2.2.1 Single nucleotide polymorphisms 
The genomes of two unrelated individuals are identical in 99.9%. The remaining 0.1% 
contains variations in the DNA sequence and is thus what makes each of us unique. An 
uncommon variatiant of an allele at a specific locus (a certain DNA-site) that is 
displayed in over 1% of a given population is termed a polymorphism. The most 
common polymorphisms in humans are the single nucleotide polymorphisms (SNPs) 
that are spread out through the genome (Sherry et al., 2001). As the name implies, a 
SNP is a DNA-site in the genome where only one single nucleotide base differs 
between individuals. Therefore, SNPs are utilized as gene markers of DNA variations 
within populations. The functional consequence of a SNP depends on where in the 
DNA it is located (Burton et al., 2005). If the SNP is positioned in an exon, i.e. a gene-
encoding region, the base-variants may result in a change of the codon (three bases that 
code for an amino acid) that will have another translation and is therefore termed non-
synonymous. Either this new codon translates to a change in amino acids (missense 
SNP) or a premature stop-codon (nonsense SNP), which alters the length of the protein. 
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Synonymous SNPs on the other hand do not affect the result of the coding sequence. A 
SNP that is positioned in a non-coding region may nonetheless influence the gene 
product. For example if the SNP is located in the promoter site, where transcript 
regulation occur, it might affect the gene expression. Also, a SNP in an intron may 
affect the mRNA splicing process, forming mRNA from preRNA that contains both 
introns and exons.  
 
 
1.2.2.2 Genetic linkage and association studies 
There are many strategies for finding genomic variations related to different diseases. 
An initial approach usually involves an analysis termed linkage study, where the entire 
genome can be scanned for shared genome region variations between affected members 
within a family (Dawn Teare and Barrett, 2005). These studies may provide a first trace 
of large genome regions that could contain a disease-causing gene. To investigate the 
influence of a specific gene, association studies may be utilized (Cordell and Clayton, 
2005). In these studies, SNPs are used as gene markers, and the aim is to find shared 
alleles between affected unrelated individuals. Several databases are provided for the 
selection of which SNPs to include in an association study; the largest one being the 
dbSNP database established by the National Centre of Biotechnology Information 
(NCBI). This database receives information from many other databases, including the 
one of the International HapMap project. The HapMap project strives to create a 
haplotype map of the human genome. A haplotype is the combination of a specific set 
of alleles displayed on a single chromosome, and the HapMap database assesses 
linkage disequilibrium (LD) to determine these haplotypes. Two genomic regions that 
are located closely on the same chromosome are often inherited together, thus no 
recombination has occurred at this site during meiosis (the formation of sperm and egg 
cells). Two genetic markers are in LD if they are inherited together more frequently 
than can be expected by chance, and accordingly the occurrence of one of them can 
predict the other (Dawn Teare and Barrett, 2005). The software Haploview further 
provides the identification of LD-blocks (also termed haplotype-blocks), i.e. SNPs that 
are in strong LD and thus often inherited together. TagSNPs, i.e. SNPs that represent 
different haplotype-blocks, can also be identified using the HapMap database. Thus, 
tagSNPs capture genetic variations across large regions of the gene, without having to 
genotype all SNPs. To assess if the control sample in an association study provides an 
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accurate representation of the whole population regarding the specific genotype and 
allele frequencies, analysis of Hardy-Weinberg equilibrium is performed. Hardy-
Weinberg equilibrium indicates that the control sample is sufficiently large and 
randomly mating, and that there is no population stratification (i.e. subpopulations with 
different descent). 
 
1.2.2.3 Risk genes for schizophrenia 
Several minor risk alleles have been presented, including variances in genes that are 
implicated in dopamine or glutamatergic signaling (Harrison and Weinberger, 2005; 
Allen et al., 2008; Lisman et al., 2008), which are the neurotransmitter systems 
predominantly associated with schizophrenia pathophysiology (see section 1.5). In 
particular, risk alleles have been found in genes encoding the catecholamine degrading 
enzyme (COMT), the dopamine D1 and D2 receptors (DRD1 and DRD2), the regulator 
of G-protein signaling 4 (RGS4), and the metabotropic glutamate receptor 3 (GRM3). 
In agreement, reports of genetic linkage and association with genes encoding enzymes 
that reduce the availability of the NMDA receptor ligands glutamate or D-serine have 
been presented (Harrison and Owen, 2003; Detera-Wadleigh and McMahon, 2006; 
Morita et al., 2007), further supporting a hypofunction of the NMDA receptors in 
patients with schizophrenia. Particular evidence has been reported for the gene 
encoding dysbindin (DTNBP1), a modulator of synaptic glutamate release, as this gene 
has been associated in independent samples with both negative and cognitive 
symptoms (Fanous and Kendler, 2008). Also the gene encoding neuregulin (NRG1), a 
neurotropic factor implicated in glutamatergic, nicotinic and GABAergic transmission 
(Falls, 2003), as well as the gene encoding the D-serine degrading enzyme D-amino 
acid oxidase (DAAO), are suggested as candidate genes for schizophrenia vulnerability, 
reviewed in (Lisman et al., 2008). Furthermore, substantial studies implicate DISC1 in 
schizophrenia. This gene is potentially involved in neurodevelopment (Ozeki et al., 
2003). Interestingly, genes encoding inflammatory proteins, e.g. the cytokines TNF and 
IL-1β, as well as the promoter site of IL-10, have also been reported to be associated 
with schizophrenia susceptibility (Schwab et al., 2003; Yu et al., 2004; Shirts et al., 
2006; Ozbey et al., 2009; Sasayama et al., 2011; Zhong et al., 2011). Contradicting 
results have however been presented in different populations, for example regarding a 
tentative IL-2 or IL-4 association to schizophrenia vulnerability (Schwarz et al., 2006; 
Watanabe et al., 2008).  
Maria Holtze 
 
 11 
In the last few years, genome wide-association studies (GWAS) have provided the 
latest technology of relatively fast large-scale genetic analyses that may include several 
hundred thousand single nucleotide polymorphisms (SNPs) across the genome. 
Interestingly, one of the first published GWAS of schizophrenia presented evidence of 
disease association with polymorphisms in the gene encoding the cytokine receptor  
IL-3Rα, which is implicated in the regulation of granulocyte and macrophage activity 
(Lencz et al., 2007). Since then, these studies have also revealed associations between 
schizophrenia and several genes involved in neurodevelopmental processes, see (Lee et 
al., 2011). For example, recent results from a large GWAS showed association with 
markers in the regions of the major histocompatibility complex (MHC), as well as in 
two genes involved in brain development, memory and cognition (NRGN and TCF4) 
(Stefansson et al., 2009). MHC is a cluster of genes encoding proteins that serve as 
antigen-presenting molecules expressed on the cell surface. Association between 
schizophrenia and polymorphisms in the MHC was confirmed by the International 
Schizophrenia Consortium (Purcell et al., 2009). The development of microarray 
technology (where multiple genome regions can be analyzed simultaneously) has 
further provided genome-wide studies of copy number variations (CNVs), i.e. 
segments of DNA, ranging from one kilobase to several megabases, that are 
duplicated, deleted or rearranged in the genome. The CNVs may interfere with 
regulatory or coding regions and can thus affect gene functions as well as gene dosage, 
reviewed in (Freeman et al., 2006; Cook and Scherer, 2008). Many neuropsychiatric 
disorders including schizophrenia, Parkinson’s disease, bipolar disorder and autism, 
have been associated with specific CNVs. Interestingly, a genetic overlap has been 
observed between CNVs in schizophrenia and neurodevelopmental disorders, such as 
autism and attention deficit hyperactivity disorder (ADHD) (O'Donovan et al., 2008; 
Owen et al., 2011). The common regions include a deletion in the location of the 
α7nACh receptor gene (CHRANA7), which is a receptor implicated in both neuregulin 
and glutamate signaling (Stefansson et al., 2008; Burbach and van der Zwaag, 2009). 
Strong evidence for a genetic overlap between schizophrenia and bipolar disorder, has 
also been shown: In a GWAS from the International Schizophrenia Consortium, 
including 6,909 individuals, a combined polygenetic contribution of several alleles of 
minor effect, involving different domains of brain development, was associated with 
increased risk of both diseases (Purcell et al., 2009).  
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No single gene encoding any enzymes within the kynurenine pathway (see section 1.3) 
had alone been associated to schizophrenia susceptibility prior to the studies included in 
this thesis. A complex genotype of several risk genes, including one SNP in the gene 
encoding tryptophan 2,3-dioxygenase (TDO), has however been associated with the 
disease (Miller et al., 2009). A polymorphism in this gene has furthermore been 
associated with vulnerability of autism (Nabi et al., 2004). It is however uncertain if an 
abnormal variance of this gene would result in increased levels of kynurenine and 
KYNA, as seen in patients with schizophrenia (Linderholm et al., 2010; 
Sathyasaikumar et al., 2010). Rather, a decrease may be expected. On the contrary, 
these metabolites are likely to be increased as a result of a polymorphism in the gene 
encoding kynurenine 3-monooxygenase (KMO). Indeed, this gene is maped to 1q42-
44, a chromosome region that has shown strong linkage to schizophrenia. Such an 
alignment was the focus of a Japanese study, but no association to schizophrenia was 
concluded (Aoyama et al., 2006). 
 
 
1.3 THE KYNURENINE PATHWAY 
Tryptophan is an essential amino acid that is necessary for protein synthesis and several 
metabolic functions, for example because it is the precursor of serotonin, melatonin and 
niacin (vitamin B3). In mammalians, tryptophan is metabolized vastly through the 
kynurenine pathway (Figure 1), named after the central degradation product 
kynurenine (Beadle et al., 1947; Peters, 1991). Induction of the kynurenine pathway 
can be triggered by several different infections (see section 1.3.2), and subsequently 
generate neuroactive and/or immune modulatory kynurenine metabolites (Stone, 1993; 
Moffett and Namboodiri, 2003; Mandi and Vecsei, 2011). Interestingly, dysfunctions 
of the kynurenine pathway, reflected for example by elevated levels of the 
neuromodulatory end product KYNA, are associated with schizophrenia (Erhardt et al., 
2001a; Schwarcz et al., 2001), a disease recently also linked to immune activation of 
the brain (Söderlund et al., 2009). 
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1.3.1 Enzymatic steps  
The first and rate-limiting enzymatic step of tryptophan degradation along the 
kynurenine pathway is the oxidative opening of the indole ring, either by indoleamine 
2,3-dioxygenase (IDO) or by TDO, forming N-formyl kynurenine. Although both 
enzymes are found in the brain, TDO appears preferentially expressed in the liver.  
N-formyl kynurenine is rapidly hydrolyzed by kynurenine formamidase to form 
kynurenine, a central metabolite in the pathway that is able to cross the blood-brain 
barrier (BBB) via the large neutral amino acid carrier (Fukui et al., 1991). Kynurenine 
is then further catabolized – the compound serves as a substrate for three distinct 
enzymes: (i) kynurenine aminotransferases (KAT 1, KAT 2, KAT 3 or mitAAT), 
forming KYNA, (ii) kynureninase (KYNU), generating antranilic acid, and (iii) KMO, 
resulting in 3-HK. The activity of the KAT enzymes may be influenced by additional 
molecular factors, such as stimulating co-substrates. Furthermore, other substrates 
may compete with the binding of kynurenine, thus making the regulation of KYNA 
production a complex machinery (Schwarcz and Pellicciari, 2002). The metabolites 
anthranilic acid and 3-HK are metabolized to 3-hydroxyanthranilic acid (3-HAA).  
3-HK may also be metabolized into the side product xanthurenic acid by the KAT 
enzymes. 3-hydroxyanthranilate 3,4-dioxygenase (HAAO) subsequently catabolizes  
3-HAA into 2-amino-3-carboxymuconic acid semialdehyde, which in turn is converted 
into either picolinic acid (PA) or quinolinic acid (QUIN). Additionally, 2-amino-3-
carboxymuconic acid semialdehyde can undergo a total oxidation via 2-amino-3-
carboxymuconate-6-semialdehyde decarboxylase (ACMSD), forming CO2 and 
adenosine triphosphate (ATP). QUIN is finally metabolized by quinolinate 
phosphoribosyltransferase (QPRT), which participates in synthesis of nicotinamide 
adenine dinucleotide (NAD+) (Stone, 1993; Moroni, 1999; Guillemin et al., 2001b; 
Schwarcz and Pellicciari, 2002; Guillemin et al., 2003b; Guidetti et al., 2007; 
Guillemin et al., 2007).  
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 Figure 1. The kynurenine pathway 
 
The enzymes of the kynurenine pathway are found both in the CNS and in the 
periphery of mammalians. Although differences regarding the activity of the 
kynurenine pathway enzymes have been reported between rodent species (Heyes et al., 
1997b; Allegri et al., 2003), it is assumed that the mechanisms of metabolite synthesis 
in the rodent and human brain are relatively similar (Guidetti et al., 1995; Schwarcz and 
Pellicciari, 2002; Kiss et al., 2003). In rats and gerbils, 60-78% of the brain kynurenine 
is reported to derive from the periphery (Gal and Sherman, 1978; Kita et al., 2002), a 
result that ought to be reflected in other mammalians as well. Nevertheless, IDO and 
TDO is expressed in a variety of cell types within the brain, including astrocytes, 
neurons and endothelial cells of the BBB (Guillemin et al., 2001b; Schroten et al., 
2001; Miller et al., 2004; Guillemin et al., 2005b; Miller et al., 2006; Guillemin et al., 
2007; Owe-Young et al., 2008). IDO has also been observed in microglia and 
macrophages, where only low expression of TDO is found (Heyes et al., 1996; 
Guillemin et al., 2003b). However, the course of kynurenine degradation within the 
CNS appears to be spatially separated, as the expressions of enzymes in the different 
pathway branches differ between specific cell types. Thus, since the KMO and KYNU 
enzymes are predominantly expressed in microglia and macrophages, these cells 
produce substantial amounts of the neurotoxic metabolite QUIN (Lehrmann et al., 
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2001; Guillemin et al., 2003b). The KAT enzymes are, however, mainly expressed in 
astrocytes (Roberts et al., 1992; Kiss et al., 2003), although these enzymes have also 
been observed in oligodendrocytes, macrophages and microglia, as well as in neurons 
(Du et al., 1992; Guillemin et al., 2003b; Wejksza et al., 2005; Guillemin et al., 2007). 
As astrocytes lack the KMO enzyme (i.e. 3-HK is not generated) and produce very 
little KYNU enzyme, synthesis of the neuroprotective metabolite KYNA is favored in 
these cells (Heyes et al., 1997a; Guillemin et al., 2001b). KYNA passes the BBB 
poorly (Fukui et al., 1991); the metabolite is removed from the brain by a probenecid-
dependent transporting process (Moroni et al., 1988), and further eliminated in the 
periphery by urinary excretion (Turski and Schwarcz, 1988). Notably, as the QPRT 
enzyme appears to be highly expressed in astrocytes, it is proposed that extracellular 
QUIN may be taken up and catabolized by these cells (Guillemin et al., 2001b), or 
removed from the brain by a probenecid-dependent transport process and eliminated 
via urinary excretion (Schwarcz and Pellicciari, 2002).  
 
 
1.3.2 Kynurenine pathway induction following immune activation 
Many infections are associated with an induction of tryptophan degradation along the 
kynurenine pathway. In humans, a number of kynurenine pathway metabolites have 
been reported to be elevated during infections or inflammatory diseases of the CNS 
(Heyes et al., 1992b). For instance, the metabolite QUIN is increased in the 
cerebrospinal fluid (CSF) of patients infected with Borrelia burgdorferi, causing Lyme 
disease (Halperin and Heyes, 1992), or with HIV-1 (Achim et al., 1993), including 
patients with AIDS dementia complex (Guillemin et al., 2005a). Increased levels of 
both PA and QUIN have also been reported in patients with severe malaria (Dobbie et 
al., 2000; Medana et al., 2002). Other reports show an association of CSF KYNA with 
infectious diseases affecting the CNS. For example, elevated CSF concentrations of this 
metabolite have been reported in individuals infected with tick-borne encephalitis 
(TBE) and in young children with cerebral malaria (Medana et al., 2003; Holtze et al., 
2011). Also, patients infected with HIV-1 display elevated levels of both kynurenine 
and KYNA in the CSF and brain (Bara et al., 2000; Atlas et al., 2007). Interestingly, 
high levels of CSF KYNA in the HIV-1 infected patients were associated with 
psychotic symptoms (Atlas et al., 2007).  
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Several experimental studies have also demonstrated a relationship between CNS 
infectious diseases and induction of the kynurenine pathway. For example, studies on 
CNS inflammation in rhesus macaques infected either with neurotropic simian 
immunodeficiency virus (SIV, the simian analog of HIV-1) or with poliovirus, reported 
elevated levels of the metabolites QUIN and KYNA in the CSF, as well as increased 
activity of the enzymes IDO, KMO and KYNU, but not KAT, in the spinal cord (Heyes 
et al., 1992a; Heyes et al., 1992c; Heyes et al., 1993). The levels of KYNA were 
increased to a lesser degree compared with QUIN, and IDO activity was increased to a 
higher extent than the other enzymes. Similar results were obtained in neurotropic 
measles virus-infected hamsters, where the infection increased the activity of HAAO 
(the enzyme that generates QUIN) in the brain, while no change in KAT activity was 
observed (Eastman et al., 1994). Increased activity of IDO, as well as increased 
concentration of QUIN, was also observed in the spinal cord of mice with HSV 
encephalitis (Reinhard, 1998). Furthermore, mice infected with the parasite 
Toxoplasma gondii displayed increased IDO activity and corresponding mRNA 
transcripts in the brain, as well as increased brain kynurenine and KYNA 
concentrations, probably mediated by stimulation of the cytokine IFN-γ (Fujigaki et al., 
2002; Silva et al., 2002; Schwarcz and Hunter, 2007). Altogether, a large body of both 
clinical and experimental studies suggests a significant role of the kynurenine pathway 
in brain immune activation.  
 
The concept of IDO induction by immune activation is widely accepted, and occurs in a 
variety of cell types both in the periphery and the CNS. Already in the 1970s it was 
shown that the bacterial endotoxin LPS could induce IDO (Hayaishi and Yoshida, 
1978). A few years later it was also shown that cytokines, the signal substances of the 
immune system, could induce IDO activity (Yoshida et al., 1981), and block the 
growth of Toxoplasma gondii (Pfefferkorn, 1984). These findings raised the idea that 
tryptophan starvation may serve as a defense mechanism of the host by reducing the 
local supply of this essential amino acid to intracellular pathogens. Ten years later, 
researchers were able to show that increased IDO activity prevents a maternal T cell-
mediated rejection of the developing fetus (Munn et al., 1998) (Mellor and Munn, 
1999). These experiments suggested that increased IDO activity has an immunotolerant 
function by inhibiting T-cells. Two different theories have emerged to explain the 
mechanism by which the T cell suppressive effect appear (Moffett and Namboodiri, 
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2003). Munn and Mellor originally proposed that depletion of tryptophan by IDO 
induction supress T-cells –  the tryptophan depletion theory. Later on, new compelling 
data signified immune functions of the tryptophan degradation metabolites – the 
tryptophan utilization theory. This view is originally based on the observation that 
several metabolites of the kynurenine pathway display immunoregulatory properties 
(see section 1.3.3), including proliferative inhibition of T cells, B cells, and natural 
killer cells (Frumento et al., 2002; Terness et al., 2002). The physiological functions of 
IDO are also widely studied in the cancer research field, were IDO induction is related 
to the prevention of an immune attack from the host (Belladonna et al., 2007; Gonzalez 
et al., 2008).  Thus, IDO shows a multifunctional role, including involvement of acute 
immune responses, as well as having an important function in mediating tolerance of 
both tumor cells and the intra-uterine fetus.  
 
The predominant and most potent IDO-inducing cytokine is IFN-γ, although other 
cytokines, such as IFN-β, TNF, IL-6 and IL-1β, also have this ability (Guillemin et 
al., 2001a; Guillemin et al., 2005b; Fujigaki et al., 2006; O'Connor et al., 2009; Kegel 
et al., 2011). In line with the observations of an induction of IDO following immune 
activation, the production of QUIN by microglia, and to a lesser extent by 
macrophages, as well as the production of KYNA by astrocytes, also increase 
following immune stimuli with IFN-γ (Guillemin et al., 2001b; Guillemin et al., 
2003b). In addition, levels of the metabolite PA are increased in pericytes of the BBB 
following a combined stimulus with IFN-γ and TNF (Owe-Young et al., 2008).  
 
Contrary to IDO, the tryptophan-breakdown enzyme TDO is not traditionally 
considered to be induced by immune activation (Saito et al., 1992; Saito et al., 1993; 
Heyes et al., 1998). However, a recent study from our laboratory demonstrates that  
IL-1β stimulation induces gene expression of both IDO and TDO in human astrocytes, 
concomitant with an increased KYNA concentration (Kegel et al., 2011). In addition, 
induction of TDO gene expression has been reported in the placenta during bacterial 
intra-uterine infections, as well as in cell cultures exposed to LPS (Manuelpillai et al., 
2003; Manuelpillai et al., 2005). This immunofacilitation of TDO have also been 
implied in a tetracycline-inducible eukaryotic system (Schmidt et al., 2009). 
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1.3.3 Physiological significance of the kynurenine pathway  
The kynurenine pathway generates several metabolites suggested to be neuroactive 
and/or immunomodulatory, see (Stone, 1993; Moroni, 1999; Moffett and Namboodiri, 
2003; Mandi and Vecsei, 2011). Most attention has been on KYNA and QUIN, but  
3-HK, 3-HAA, and PA should also be included in this category. However, also the 
pivotal metabolite kynurenine exerts physiological functions, such as regulation of 
vascular tone (Wang et al., 2010), an important and profound mechanism in 
inflammatory responses. Kynurenine was also recently suggested to directly mediate 
both a tumor promoting and a T cell suppressive effect (Opitz et al., 2011). Although 
the kynurenine pathway metabolites are generally found in lower concentrations in the 
brain, CSF and spinal cord than in the periphery, their presence in the CNS is 
undeniably relevant for physiological and pathologic conditions.  
 
KYNA was originally detected in canine urine (Liebig, 1853). More than a century 
later, KYNA was found in the mammalian brain (Moroni et al., 1988; Turski et al., 
1988) and has since then been widely studied as a neuroactive compound. In the brain, 
KYNA has a unique receptor profile. At low concentrations, KYNA antagonizes the 
co-agonist glycine site of the NMDA receptor (IC50 ≈ 8-15 µM, i.e. the ligand 
concentration that yields 50% receptor inhibition) (Stone, 1993; Parsons et al., 1997), 
and the α7nAch (IC50 ≈ 7 µM) (Hilmas et al., 2001). At higher concentrations, the 
glutamate recognition site of the NMDA receptor (IC50 ≈ 200-500 µM) and the  
α-amino-3-hydroxy-5-methy-4-isoxazole propionate (AMPA)/kainate receptors (IC50 in 
the millimolar range) are also blocked (Kessler et al., 1989). As the level of KYNA in 
the rodent brain is in the nM range, far below the levels required for antagonizing the 
receptors, the physiological significance has been under debate. However, astrocytes 
play an important role in regulating synaptic transmission and accordingly, these glial 
cells have been shown to intimately surround glutamatergic synapses (Newman, 
2003). Since KYNA is produced in astrocytes, the local concentration within the 
synapse should be considerably higher compared to that received from analysis of 
whole brain tissues. Experimental evidence show that endogenous concentrations of 
KYNA tonically modulate firing of dopamine neurons and affect glutamate release 
(Erhardt et al., 2009; Konradsson-Geuken et al., 2010; Pocivavsek et al., 2011b). 
Importantly, KYNA is implicated in the pathophysiology of several psychiatric 
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disorders (see section 1.5.3), and increased concentration of KYNA is found in the 
CNS of patients with schizophrenia (Erhardt et al., 2001a; Schwarcz et al., 2001; 
Nilsson et al., 2005; Linderholm et al., 2010; Sathyasaikumar et al., 2010), bipolar 
disorder (Olsson et al., 2010), and suicide attempters with major depression 
(Linderholm, 2010), as well as in patients with neurodegenerative disorders like 
Alzheimer’s disease or amyotrophic lateral sclerosis (ALS) (Baran et al., 1999; Ilzecka 
et al., 2003). Notably, cognitive impairments are recognized in all of these disorders 
(Andreasen, 1995; Martinez-Aran et al., 2004; Hinkelmann et al., 2009; Ballard et al., 
2011; Giordana et al., 2011). A physiological role of KYNA elevation might be 
related to the neuroprotective effects of the compound. At very least, this could be the 
case regarding the neurodegenerative disorders where KYNA may balance neurotoxic 
events. The neuroprotective property of KYNA is probably mediated by blockade of 
the NMDA receptors and possibly also via decreased glutamate release by antagonizing 
the α7nACh receptors (Foster et al., 1984; Stone, 1993; Urenjak and Obrenovitch, 
2000; Zwilling et al., 2011).  
 
Interestingly, KYNA is also reported to encompass immunomodulatory properties, 
including an anti-inflammatory effect, reviewed in (Mandi and Vecsei, 2011). In the 
periphery, for example in mononuclear cells and in blood monocytes, KYNA has been 
found to attenuate the production of TNF (Wang et al., 2006; Tiszlavicz et al., 2011). 
This cytokine is a mediator of early pro-inflammatory immune responses, thus 
promoting activation of several other cytokines, including IL-1, IL-6 and IL-8 (Bradley, 
2008). As TNF also can be released from astrocytes and microglia (Chung and 
Benveniste, 1990), and is associated with potentiated glutamate-induced neuronal cell 
death (Zou and Crews, 2005), it is suggested that inhibition of TNF production could 
contribute to the neuroprotective properties of KYNA (Mandi and Vecsei, 2011). This 
effect of KYNA is possibly mediated via a blockade of α7nACh receptors. However, 
recent reports reveal that KYNA also serves as an agonist on the G protein-coupled 
receptor 35 (GPR35), a receptor found in several immune cells with high expression in 
monocytes, T cells, neutrophils, and dendritic cells (Wang et al., 2006; Fallarini et al., 
2010). The immunomodulatory effects of KYNA may thus include affinity to α7nACh 
and/or GPR35 receptors.  
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The kynurenine pathway metabolite QUIN has been frequently studied in the 
mammalian brain. Ever since the discovery of its ability to produce seizures in the 
mouse (Lapin, 1978), QUIN has been regarded as a neuroactive compound. In the 
brain, QUIN is an NMDA receptor agonist with excitatory actions, but also with 
neurotoxic and convulsive properties (Stone and Perkins, 1981; Schwarcz et al., 1983; 
Foster et al., 1984). Thus, potential neurological damage by QUIN is suggested to 
impact the pathogenesis of neurological disorders. Increased levels of CNS QUIN are 
indeed found in several neurodegenerative disorders, including Huntington’s disease, 
Alzheimer’s disease, ALS and AIDS dementia complex (Guillemin and Brew, 2002; 
Guidetti et al., 2004; Guillemin et al., 2005a; Chen et al., 2010). In the brains of 
patients with Huntington’s disease, levels of the QUIN precursor 3-HK are also 
reported to be elevated (Guidetti et al., 2004). Notably though, CSF QUIN in patients 
with inflammatory diseases are found in substantially higher concentrations than those 
observed in patients with neurodegenerative disorders (Heyes et al., 1992b). Indeed, 
QUIN is also involved in important immunomodulatory functions, reviewed in (Stone, 
2001; Mandi and Vecsei, 2011). In particular, the suppression of T cells related to IDO 
activation (see section 1.3.2) might reflect the actions of QUIN and its precursor  
3-HAA, as these kynurenine pathway metabolites induce apoptosis of T cells (Fallarino 
et al., 2002). The latter metabolite, in analogy with 3-HK and kynurenine, is also 
reported to modulate the cytokine balance (Molano et al., 2008). Cytokine imbalance 
has also been observed in patients with schizophrenia (Muller and Schwarz, 2010). 
However, this is not reported to occur in the CNS and the importance of an imbalance 
in the periphery might be difficult to interpret in regard to a neuropsychological disease 
like schizophrenia. Another immune-related function of QUIN is the ability to serve as 
a substrate for production of the ubiquitous co-enzyme NAD+ that is essential for many 
cellular reactions, including ATP synthesis and DNA repair, reviewed in (Moffett and 
Namboodiri, 2003). While QUIN is rapidly converted to NAD+ in the liver, QUIN is 
stored in several types of immune cells (Moffett et al., 1993) and may potentially serve 
to prevent NAD+ depletion following oxidative DNA damage springing from an 
immune response, see (Stone, 2001; Moffett and Namboodiri, 2003). Indeed, whereas 
microglia and macrophages are able to produce some QUIN under normal conditions, 
immune activation greatly promotes the synthesis of this kynurenine metabolite. In the 
brain, this effect is especially attributed to infiltrating macrophages, as these cells are 
suggested to synthesize the major proportion of QUIN during brain inflammatory 
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diseases (Guillemin et al., 2003b). Furthermore, the QUIN precursors of the kynurenine 
pathway, 3-HK and 3-HAA, are both found to be neurotoxic, including apoptotic 
properties (Okuda et al., 1998; Morita et al., 2001). Although the neurotoxic 
mechanism is not fully established for 3-HAA, 3-HK is a generator of toxic free 
radicals (Eastman and Guilarte, 1989).  
 
The chelating metal ion agent PA was the first kynurenine pathway metabolite to be 
recognized as an immune modulator by being able to stimulate chemokine release of 
macrophages (Ruffmann et al., 1984; Bosco et al., 2000). Subsequently, it was shown 
that PA is involved in several immunological functions, for instance having an 
antiviral effect against HIV-1 and human HSV type 2 (Fernandez-Pol et al., 2001) as 
well as exhibiting an antimicrobial effect against Mycobacterium avium complex 
(MAC) organisms by potentiating macrophage activity (Cai et al., 2006). The capacity 
to induce expression of nitrite and nitric oxide synthase in macrophages has further 
implicated PA in inflammatory actions. PA has also been implied as a neuroactive 
metabolite of the kynurenine pathway (Melillo et al., 1993; Melillo et al., 1994). In 
this regard, PA effectively blocks QUIN neurotoxicity, although its neuroprotective 
effect differs from that of KYNA (Jhamandas et al., 1990; Beninger et al., 1994). 
However, PA seems to be less potent than KYNA in antagonizing the QUIN-induced 
neurotoxicity (Jhamandas et al., 1990). Although the immediate precursor enzyme of 
PA has only been found in low levels in the human brain (Fukuoka et al., 2002; Pucci 
et al., 2007), elevated levels of CSF PA have been detected in patients with infectious 
diseases, such as cerebral malaria infection (Medana et al., 2002; Medana et al., 2003). 
Furthermore – in addition to macrophages – astrocytes, neurons and pericytes of the 
BBB are able to produce PA (Guillemin et al., 2001b; Guillemin et al., 2007; Owe-
Young et al., 2008), indicating that this tryptophan metabolite is an 
immunomodulating and/or neuroactive mediator also in the brain. 
 
 
1.4 VIRUS INFECTIONS AND CNS IMMUNE RESPONSES 
The CNS was previously considered to have an immune-privileged status. This 
conservative view was based on the findings in the mid-1900s of an absent immune 
reaction following allogeneic transplants. The absence or low expression of MHC 
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molecules on resident cells of the CNS, the absence of a proper lymphatic system, and 
the presence of the BBB further supported this notion. Today, this view is somewhat 
modified and it is now clear that the CNS is not completely isolated from the peripheral 
immune system. A complex and bi-directional communication does indeed exist 
between these systems, reviewed in (Dantzer et al., 2000; Quan and Banks, 2007; 
Dantzer et al., 2008; Wilson et al., 2010; Trakhtenberg and Goldberg, 2011). Examples 
are communication via the vagus nerve or the circumventricular organs (i.e. structures 
in the brain that lack a BBB), where cytokines and other circulating molecules are able 
to directly interact with the CNS. Interactions between the two systems can also occur 
through cytokine transport across the BBB as well as through secretion of 
prostaglandins by the BBB cells. Although immune activation of the CNS is rigorously 
controlled under normal conditions, for example through restriction of MHC molecule 
expression and suppression of T cell proliferation, reviewed in (Griffin, 2003), it 
involves a complex network of innate immune cells, such as brain resident microglial 
cells that are able to scan the brain parenchyma for injury, tumors or infection. Also, 
BBB-guarding macrophages ensure immediate detection of a pathogenic attack 
(Kreutzberg, 1996), reviewed in (McGavern and Kang, 2011). The blood-CSF barrier 
(formed by the CSF-producing choroid plexus and the arachnoid membrane) is also 
protected by macrophages. In the event of a pathogen invasion, macrophages can enter 
the CNS and be recruited to the site of infection (Raivich and Banati, 2004). Astrocytes 
are also important mediators of the innate immune system within the CNS, for example 
by expressing many receptors involved in innate immune responses, such as Toll-like 
receptors (TLR) and scavenger receptors, and by releasing cytokines following immune 
stimulation, reviewed in (Farina et al., 2007). Essentially though, one must bear in mind 
that the CNS immune system is a fairly novel field of research and the interpreted 
actions may still be ambiguous.  
 
The nature of the immune responses in early life may not fully reflect the events in 
adulthood, as the immune system develops throughout the first years of life in humans, 
reviewed in (Ygberg and Nilsson, 2011). Furthermore, the BBB might be compromised 
during neonatal life, for example indicated by an efficient infiltration into the rodent 
brain of systemically administered cytokines, reviewed in (Watanabe et al., 2010). 
Even though recent studies demonstrated that the formation of a functional BBB occurs 
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already during embryogenesis in rodents (Daneman et al., 2010), the maturation phase 
of the BBB seems to occur in postnatal life (Liebner et al., 2011). 
 
Viruses rarely access the CNS directly. The first immune response to virus infections, 
including neurotropic viruses, therefore usually occurs in the periphery. Thus, 
neurotropic viruses normally induce infections through the gastrointestinal or 
respiratory tracts. Although rare in the mature brain, viruses may pass the CNS barriers 
using different strategies, reviewed in (McGavern and Kang, 2011). Following a viral 
invasion the expression of type I interferons (IFN-α/β) is stimulated, promoting an anti-
viral effect. A fast production of these cytokines is important for host survival as it 
limits virus spread and replication. In the brain, the type I IFNs can be released from 
astrocytes and microglia, and to some extent also from neurons, reviewed in (Paul et 
al., 2007). Infected neurons are also likely to produce different chemokines and 
cytokines such as IFN-γ and IL-6, thus mediating activation signals to microglia and 
astrocytes (Maciejewski-Lenoir et al., 1999; Neumann, 2001), reviewed in (Griffin, 
2003). Together with perivascular macrophages, astrocytes and microglia serve as 
important components of the innate immune response in the CNS. By expressing for 
example TLR, astrocytes and microglia are able to recognize conserved structures on 
invading pathogens, such as viral nucleic acids (Paul et al., 2007). The TLR signaling 
further induces the release of a symphony of inflammatory mediators, which is specific 
to the virus infection but commonly includes the cytokines IL-1, IL-6, IL-12, TNF, as 
well as different chemokines, see (Falsig et al., 2008). An innate immune response to 
viral infections may also include the expression of inducible nitric oxide synthase 
(iNOS), which is the inducible form of the enzyme responsible for nitric oxide (NO) 
production. This mechanism is stimulated by pro-inflammatory cytokines such as  
IFN-γ, IL-1β and TNF (Saha and Pahan, 2006).  
 
Following activation of the innate immune system, peripheral leukocytes enter the CNS 
across the BBB and are recruited to the site of infection, see (Raivich and Banati, 2004; 
Becher et al., 2006). However, initial induction of the adaptive (i.e. antigen-specific) 
immune response, such as activation of T cells and B cells, is thought to occur outside 
the CNS. It is also notable that during a peripheral immune response, the permeability 
of the BBB is enhanced (e.g. mediated by TNF), and even in the absence of a CNS 
infection, activated T cells cross the BBB to screen for any possible pathogen 
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infiltrations at this site, reviewed in (Hickey, 2001). Cells in the CNS do not normally 
express MHC molecules. However, during a viral CNS immune response, the 
expression of MHC class I molecules (which present antigens to CD8+ T cells) and 
class II molecules (which present antigens to CD4+ T cells) is induced (Pope et al., 
1998; Kimura and Griffin, 2000). Although several cell types in the CNS are able to 
produce MHC molecules during an infection, microglia are the most efficient antigen-
presenting cells (Neumann, 2001). As neurons are non-renewable and thus fairly 
resistant to apoptosis, viral clearance from these cells may occur in a non-cytolytic 
manner. This process is generally dependent on antibody responses and includes the 
inhibition of intracellular viral replication (Griffin, 2010). In addition to antibodies, 
both CD4+ and CD8+ T cells contribute to the non-cytolytic viral clearance via IFN-γ 
expression, mediating an antiviral effect (Binder and Griffin, 2001), see (Guidotti and 
Chisari, 2001). For example, a more rapid reduction of viral RNA from neurons is 
observed in the presence of CD8+ T cells (Kimura and Griffin, 2000).  
  
 
1.5 HYPOTHESES OF SCHIZOPHRENIA PATHOPHYSIOLOGY 
The complexity of schizophrenia, including the heterogeneous subset of symptoms, has 
during the years of schizophrenia research resulted in a number of theories regarding 
the disease pathophysiology encompassing many neurotransmitter systems in the brain. 
The most established hypothesis suggest alterations predominantly in the dopamine and 
glutamate systems of the brain, see (Carlsson et al., 2004; Javitt, 2007). 
 
 
1.5.1 Dopamine in schizophrenia 
1.5.1.1 Brain dopamine pathways and receptors 
The mammalian brain contains four major dopaminergic systems (Moore and Bloom, 
1978; Le Moal and Simon, 1991). The nigrostriatal dopamine pathway, projecting from 
substantia nigra in the midbrain and terminating in the dorsal part of the striatum, is an 
important regulator of motor functions. Degeneration of the dopamine neurons in the 
nigrostriatal dopamine system underlies the pathophysiology of Parkinson’s disease 
(Hornykiewicz and Kish, 1987), and this pathway is also associated with the 
extrapyramidal side effects caused by antipsychotic drugs. The mesocorticolimbic 
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dopamine pathway originates in the ventral tegmental area in the midbrain and 
terminates in either subcortical (limbic) areas, i.e. the mesolimbic dopamine pathway, 
or the prefrontal cortex, i.e. the mesocortical dopamine pathway. The mesolimbic 
dopamine pathway is involved in emotional control, motivation and reward, as well as 
locomotor behavior in rodents. The mesocortical dopamine pathway regulates working 
memory, executive planning, organization, attention, and social behavior. Finally, the 
tuberoinfundibular dopamine pathway originates in the hypothalamus and projects to 
the pituitary, and is involved in endocrine control. 
 
Dopamine neurotransmission is mediated by five dopamine receptors, divided into two 
receptor families based on their pharmacological and biochemical properties: The D1-
like and D2-like receptors. The D1-like receptors are subdivided into D1 and D5 
receptors, and the D2-like receptor family includes D2, D3 and D4 receptors (Jaber et al., 
1996). The dopamine receptors are suggested to be involved in different functions 
related to a number of brain disorders, including not only schizophrenia and 
Parkinson’s disease, but also drug addiction, attention deficit disorders, psychosis and 
mood disorders.   
 
1.5.1.2 The dopamine hypothesis of schizophrenia 
The dopamine hypothesis, presented almost 50 years ago, originally proposed that a 
general hyper-dopaminergic activity was the underlying cause of psychotic symptoms 
in patients with schizophrenia (Carlsson and Lindqvist, 1963). This theory was initially 
supported only by pharmacological evidence. In particular, by the fact that therapeutic 
effectiveness of antipsychotic drugs is attributed to a specific blockade of D2 receptors 
(Seeman and Lee, 1975; Creese et al., 1976; Seeman et al., 1976), and by the 
observation that dopamine-releasing drugs, such as amphetamine, may induce a 
psychotic state in healthy individuals and exacerbate psychotic symptoms in patients 
with schizophrenia (Angrist et al., 1974; Snyder et al., 1974). In the past decades, brain 
imaging techniques have revealed a hyper-reactive state of dopaminergic 
neurotransmission in patients with schizophrenia, as reflected by an increased 
dopamine release in the striatum (Abi-Dargham et al., 1998; Lindstrom et al., 1999) 
and a potentiated striatal release following amphetamine administration (Laruelle et al., 
1996; Breier et al., 1997; Abi-Dargham et al., 1998; Laruelle and Abi-Dargham, 1999).  
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Antipsychotic drugs used today block dopamine D2 receptors. In most patients typical 
antipsychotic drugs (i.e. classical neuroleptics), with pronounced D2 receptor 
antagonism, are not sufficient treatment, since these therapeutics do not improve 
cognitive functioning or affect negative symptoms (King, 1998; Breier, 1999; Meltzer 
et al., 1999). These observations led to a reformulation of the dopamine hypothesis to 
encompass impairment in D1 receptor-mediated signaling in the prefrontal cortex. 
Accordingly, the dopamine imbalance hypothesis of schizophrenia was presented, 
suggesting that the cognitive dysfunctions and negative symptoms are mainly due to a 
persistent deficit in prefrontal cortical dopamine functions, whereas the positive 
symptoms may arise from an intermittent facilitation of subcortical dopamine 
transmission in the limbic system via D2 receptors (Weinberger et al., 1986), see (Davis 
et al., 1991; Svensson, 2003). Although this might explain the episodic psychotic states 
and the more stable negative symptoms and cognitive impaired functions (Green et al., 
2000), the etiology of this putative imbalance in dopamine neurotransmission still 
remains elusive.   
 
 
1.5.2 Glutamate in schizophrenia 
1.5.2.1 Brain glutamate system and receptors 
The amino acid glutamate is the major excitatory neurotransmitter of the mammalian 
brain. It is found in almost every brain region and is involved in most aspects of brain 
functions. Glutamate is crucial for synaptic plasticity, memory and learning, and thus of 
great interest for schizophrenia pathophysiology (McEntee and Crook, 1993). Two 
glutamate receptor families have been described: The ionotropic glutamate receptors 
(NMDA, AMPA and kainate receptors), which are ligand-gated ion channel receptors, 
and the metabotropic glutamate receptors (mGluR), which are G-protein coupled 
receptors (Ozawa et al., 1998). The NMDA receptor, which is of particular interest for 
schizophrenia pathophysiology, is a complex receptor that is both ion- and voltage-
gated. Thus, receptor activation requires not only agonist binding and depolarization of 
the cell, but also D-serine or glycine binding at the co-agonistic allosteric site, 
concomitant with several additional regulatory agents, resulting in removal of the 
physical Mg2+ block within the ion channel. The NMDA receptors are arranged in 
heteromeric complexes composed of the subunits NR1, NR2 and NR3, the glycine site 
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being located on the NR1 subunit. As the receptor subunits express distinctive ligand-
binding sites, and as different subunits are able to modify the receptor properties, the 
composition of these complexes is crucial for NMDA receptor functioning. Activation 
of the NMDA receptor may cause a long-lasting enhancement of the synaptic efficacy, 
a process that is thought to regulate functions of memory and learning (Lynch, 2004). 
An overstimulation of the NMDA receptor may, however, cause exitotoxicity, probably 
as a result of an excessive Ca2+ influx into the cell, and thus lead to neuronal damage 
and even cell death (Meldrum and Garthwaite, 1990). 
  
1.5.2.2 The glutamate deficiency theory of schizophrenia 
In the mid-twentieth century, clinicians observed that administration of the dissociative 
anesthetic drug PCP produced severe side effects as it induced a psychotic state in 
mentally healthy patients (Luby et al., 1959; Bakker and Amini, 1961; Ban et al., 
1961). In the 1970s PCP became a drug of abuse, and intoxicated patients with long-
term usage were often indistinguishable from patients with schizophrenia (Yesavage 
and Freman, 1978). It was however not until 1985 that PCP was recognized as an 
NMDA receptor antagonist (Snell and Johnson, 1985). This action of PCP came to 
support the glutamate deficiency theory of schizophrenia – suggesting a hypofunction 
in glutamatergic neurotransmission to underlie the pathophysiology. The hypothesis 
was initially formulated by Kim and co-workers, who reported low glutamate levels in 
the CSF of patients with schizophrenia (Kim et al., 1980). Mounting evidence 
supporting this theory has since then been presented. In particular, non-competitive 
inhibition of the NMDA receptor, e.g. by PCP or ketamine, has been shown to induce 
positive and negative symptoms of schizophrenia as well as cognitive dysfunctions 
(Javitt and Zukin, 1991; Krystal et al., 1994; Jentsch and Roth, 1999). These drugs may 
furthermore worsen or re-awaken symptoms in patients with schizophrenia (Itil et al., 
1967; Malhotra et al., 1997; Lahti et al., 2001). In addition, several studies report that 
competitive NMDA receptor blockade, as well as antagonism of the glycine site of the 
NMDA receptor, may induce psychomimetic effects (Kristensen et al., 1992; Grotta et 
al., 1995; Yenari et al., 1998). Furthermore, experimental studies in rodents have shown 
that systemic administration of PCP is associated with increased activity of midbrain 
dopamine neurons (French et al., 1993). Subchronic blockade of the NMDA receptor 
through PCP treatment of rats has been reported to increase mesolimbic dopamine 
release, and also to reduce dopamine release in the prefrontal cortex (Jentsch et al., 
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1997; Jentsch et al., 1998; Jentsch and Roth, 1999). A relationship between the 
glutamate deficiency theory and the dopamine hypothesis of schizophrenia was 
subsequently demonstrated through imaging studies in humans. Thus, in line with 
observations in patients with schizophrenia (see section 1.5.1.2), ketamine 
administration to healthy volunteers increases dopamine levels in the striatum and 
potentiates amphetamine-induced dopamine release (Breier et al., 1998; Kegeles et al., 
2000). Over the years, it has become increasingly evident that the imbalance of 
dopamine neurotransmission in schizophrenia may be secondary to NMDA receptor 
hypofunction, see (Svensson, 2000; Laruelle et al., 2003). Still, the underlying cause of 
this brain dysfunction remains to be determined. 
 
 
1.5.3 The kynurenic acid hypothesis of schizophrenia 
Since the initial discovery in 2001 of increased KYNA levels in the CSF and the 
prefrontal cortex of patients with schizophrenia (Erhardt et al., 2001a; Schwarcz et al., 
2001), these findings have been confirmed in several clinical studies, including drug-
naïve, first episode patients and patients treated with antipsychotic drugs (Nilsson et al., 
2005; Erhardt et al., 2007; Erhardt et al., 2009; Linderholm et al., 2010; 
Sathyasaikumar et al., 2010). The clinical findings have formed the basis of the 
kynurenic acid hypothesis of schizophrenia. KYNA, a tryptophan metabolite (Figure 
1), shows a unique receptor-binding profile by blocking the co-agonistic glycine site of 
the NMDA receptor and the α7nACh receptor (see section 1.3.3), thus partly sharing 
pharmacological properties with the psychotomimetic drugs PCP and ketamine. 
Accordingly, the compound may induce deficits in both glutamatergic and cholinergic 
neurotransmission, features commonly implicated in schizophrenia.  
 
During the past decade, the kynurenic acid hypothesis has been strengthened by a large 
number of experimental studies, giving robust support for a physiological significance 
of KYNA. Electrophysiological studies in vivo show that KYNA affect dopamine 
neurotransmission. Thus, elevated endogenous concentration of the compound in the 
rat brain is associated with increased midbrain dopamine firing (Erhardt et al., 2001b; 
Erhardt and Engberg, 2002; Nilsson et al., 2006; Schwieler et al., 2006; Linderholm et 
al., 2007; Olsson et al., 2009), in analogy with systemically administered NMDA 
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receptor antagonists, such as MK-801 and PCP (French et al., 1993; Zhang et al., 
1993). The somewhat paradoxical increase in firing rate following administration of an 
NMDA receptor antagonist may be explained by a disinhibition of dopamine neurons 
via blockade of GABAergic interneurons (Zhang et al., 1993; Erhardt and Engberg, 
2002). Hyperactivity in the mesolimbic dopamine pathway may cause psychosis in 
patients with schizophrenia and it is possible that elevation of brain KYNA contributes 
to these symptoms. A reduction in endogenous brain KYNA, by administration of 
selective cyclooxygenase (COX)-2 inhibitors, is associated with a dampened activity of 
midbrain dopamine neurons (Schwieler et al., 2006; Schwieler et al., 2008). Such 
results demonstrate that brain KYNA tonically modulate dopamine neurotransmission. 
In this context it could be worth mentioning that inhibition of COX-2 has been 
associated with beneficial antipsychotic effects when added to conventional 
antipsychotic drugs (Muller et al., 2002). Notably, the antipsychotic drug clozapine, 
known to be superior in the treatment of schizophrenia, have been shown to display a 
partial agonistic action at the glycine site of the NMDA receptor (Schwieler et al., 
2008). Thus, a hypoglutamatergic state, induced by elevated levels of KYNA, would be 
restored thanks to the agonistic properties of clozapine. If accurate, such an effect may 
form part of the therapeutic action of clozapine. 
 
Additional support for the KYNA hypothesis is provided by the observation that sub-
chronic elevation of KYNA in adult rodents potentiates amphetamine-induced 
dopamine release in the nucleus accumbens (Olsson et al., 2009). This is in consonance 
with the hyper-responsiveness to D-amphetamine observed in patients with 
schizophrenia (Laruelle and Abi-Dargham, 1999). Furthermore, KYNA is associated 
with a number of functional domains implicated in schizophrenia. A large body of 
studies shows the involvement of NMDA or α7nACh receptor in cognitive functions, 
see (Robbins and Murphy, 2006; Albuquerque et al., 2009). Thus, blockade of these 
receptors, e.g. by KYNA, may induce the cognitive deficits that make up the core 
symptoms of schizophrenia. Pharmacologically increased brain KYNA in rats disrupt 
sensory motor gating and auditory sensory gating, as well as impair cognitive functions, 
such as contextual processing and learning and working memory (Shepard et al., 2003; 
Erhardt et al., 2004; Chess and Bucci, 2006; Chess et al., 2007; Chess et al., 2009). 
Local hippocampal infusions of kynurenine, which increased extracellular KYNA, also 
impaired cognitive performance of the rat in the Morris Water Maze test (Pocivavsek et 
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al., 2011b). In line with these studies, mice with a targeted deletion of KAT 2 (the 
enzyme that converts kynurenine to KYNA) display reduced levels of brain KYNA, 
and enhanced cognitive performance, including object exploration and recognition, 
passive avoidance, and spatial learning (Potter et al., 2010). Similar cognitive 
improvements were recently reported following local infusion in the hippocampus of a 
pharmacological KAT 2 inhibitor (Pocivavsek et al., 2011b). 
 
The synthesis of KYNA is mainly driven by the concentration of its precursor 
kynurenine (Schwarcz and Pellicciari, 2002). The IDO/TDO enzymes, and 
subsequently the availability of kynurenine, are thus suggested to be rate limiting for 
the production of KYNA. Furthermore, KYNA synthesis is indirectly controlled by 
KMO since a reduced activity of this enzyme would shunt the metabolism of 
kynurenine towards KYNA. Indeed, patients with schizophrenia have elevated 
concentrations of kynurenine in the CSF and in brain cortical regions (Miller et al., 
2006; Miller et al., 2008; Linderholm et al., 2010; Sathyasaikumar et al., 2010). Thus, 
the increased brain KYNA levels observed in schizophrenia may possibly be a 
consequence of increased brain IDO/TDO expression and/or reduced activity of KMO. 
Indeed, elevated levels of TDO at the mRNA and protein level have been observed in 
schizophrenia (Miller et al., 2004; Miller et al., 2006). Importantly, activation of IDO 
following immune activation is frequently reported, see (Widner et al., 2000; Puccetti, 
2007). Induction of the kynurenine pathway, as displayed by increased metabolite 
levels in the CSF, has furthermore been reported in infectious diseases involving the 
brain (Heyes et al., 1992b; Medana et al., 2002; Atlas et al., 2007; Holtze et al., 2011). 
An involvement of brain immune activation in schizophrenia was recently 
demonstrated where the pro-inflammatory cytokine IL-1β was elevated in CSF from 
first episode patients (Söderlund et al., 2009). Recent data from our laboratory 
interestingly show that this cytokine induces gene expression of both IDO and TDO, as 
well as increase levels of KYNA in human astrocytes (Kegel et al., 2011). The 
underlying cause of the deficits in the kynurenine pathway in patients with 
schizophrenia might thus involve a pathological cytokine expression in the CNS, 
possibly paralleled by genetic implications. 
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to evaluate if disturbances in the kynurenine pathway 
may contribute to the development of neuropsychiatric disorders. First, we investigated 
if an abnormal activity in the kynurenine pathway could serve as a possible link 
between CNS infection in early life and later development of schizophrenia. Second, 
we investigated if development of schizophrenia could involve a genetic variation in 
the kynurenine pathway. 
 
The specific aims are: 
 
1) To analyze if the mouse-adapted neurotropic strain of influenza A virus 
(WSN/33) could induce the kynurenine pathway in vitro and in vivo in  
wild-type and Tap1-/- mice (lacking CD8+ T-cells). 
 
2) To investigate potential long-term effects of the neonatal influenza A/WSN/33 
virus infection on sensorimotor gating and on D-amphetamine-induced 
locomotor activity in adult mice. 
 
3) To investigate if transiently elevated levels of endogenous brain KYNA in 
postnatal life could mimic the long-term behavioral effects of the neonatal 
influenza A/WSN/33 virus infection observed in adult mice.  
 
4) To examine genetic variations in the kynurenine pathway by studying a possible 
association between polymorphisms in the KMO gene and schizophrenia. 
 
5) To examine a potential association between polymorphisms in the KMO gene 
and levels of CSF KYNA.  
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3 METHODOLOGICAL CONSIDERATIONS 
A detailed description of the experimental protocol can be found in each separate paper. 
Here, only methodological aspects are presented. 
 
 
3.1 ANIMALS 
All animal experiments were approved by the ethical committee of Northern 
Stockholm, Sweden, and performed in accordance with the accepted protocol. Every 
effort was made to minimize both the number of animals utilized and animal suffering.  
 
Wild-type C57BL/6 mice used in paper I were bred at the Department of 
Microbiology, Tumor and Cell Biology, Karolinska Institutet. In paper II and III the 
wild-type C57BL/6 mice were obtained from Scanbur AB, Sweden. The influenza A 
virus-infected mice and their respective controls (paper II and III) were bred at the 
Department of Neuroscience, Karolinska Institutet, Sweden. Mice treated with  
L-kynurenine and their corresponding saline treated controls (paper III) were bred at 
the Department of Physiology and Pharmacology, Karolinska Institutet, Sweden.   
 
In paper II mice with a targeted disruption of the gene encoding “Transporter 
associated with antigen processing 1” (Tap1-/-) generated on C57BL/6 background were 
obtained from The Jackson Laboratory, USA and bred at the Department of 
Neuroscience, Karolinska Institutet, Sweden. The transporter associated with antigen 
processing (TAP) is required for the intracellular transport of peptides to MHC class I 
molecules in the endoplasmatic reticulum (Van Kaer et al., 1992). Mice with a null 
mutation in the Tap1 gene thus express reduced levels of MHC class I molecules. This 
results in a lack of functional CD8+ T-cells. These cells are considered important for 
viral clearance in adult mice, including clearance of virus from the brain parenchyma 
(Stevenson et al., 1997a; Stevenson et al., 1997b). Indeed, in adult mice, influenza A 
virus infection is cleared from the brain more rapidly in wild-type C57BL/6 mice than 
in Tap1-/- mice (Mori et al., 1999; Aronsson et al., 2001). We included the 
immunodeficient Tap1-/- mice in our studies to further investigate the outcome of 
influenza A virus infection, as previous reports indicated a more pronounced innate 
immune response in these mice, as well as behavioral deficiencies in contrast to wild-
type mice (Asp et al., 2009). 
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All mice were housed under standard, pathogen-free, laboratory conditions with free 
access to food pellets and tap water in a light-controlled room (12 h light/dark cycle, 
light on at 6 a.m.). Pregnant mice were kept in a single cage and the male pups (utilized 
in behavior assessments) were separated after a weaning period of three weeks.   
 
 
3.2 DRUGS 
To increase the concentration of endogenous brain KYNA, the precursor kynurenine 
was administered to mice in paper III. L-kynurenine sulfate salt (Sigma Aldrich) was 
dissolved in distilled H2O and adjusted with NaOH to approximately pH 8.2.  
D-amphetamine was used to investigate behavioral aberrations, similar to those seen in 
schizophrenia, in L-kynurenine-treated or infected mice (paper III). D-amphetamine 
hemisulfate salt (Sigma Aldrich) was dissolved in 0.9% NaCl. This psychostimulant 
drug increases dopamine efflux and causes behavioral hyperactivity in animals.  
 
 
3.3 NEONATAL TREATMENT 
In our studies, two types of neonatal treatments were carried out in separate sets of 
mice: Influenza A virus infection at P3 or P4 and L-kynurenine treatment at P7-P16. 
 
3.3.1 Influenza A/WSN/33 virus infection of mice  
In paper I, II and III, influenza A/WSN/33 virus, obtained from Dr. S. Nakajima (The 
Institute of Public Health, Tokyo, Japan), was utilized to model a viral CNS infection in 
mice. This mouse-adapted and neurotropic strain of influenza virus is developed from 
the human influenza A virus, originally isolated in 1933 by Wilson Smith and 
coworkers (Smith et al., 1933; Francis and Moore, 1940). Injection of this strain of the 
influenza A virus into the olfactory bulb of young adolescent mice has previously been 
reported to decrease anxiety and impair spatial learning in adulthood, as well as altering 
the expression of genes involved in the regulation of synaptic activities (Beraki et al., 
2005). Also, when administered in such manner the virus targets regions in the brain 
parenchyma that are implicated in neuropsychiatric disturbances (Mori et al., 1999). In 
this thesis, the influenza A virus was injected intraperitonatally (i.p.) to mimic a 
hematogenous route of the infection from the mother to the fetus. This method was 
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based on the neurodevelopmental theory of schizophrenia and particular the hypothesis 
that maternal infection is a risk factor for developing the disease (see section 1.2.1). In 
line with this theory, the time-point selected for the influenza A virus infection, P3 or 
P4, corresponds to approximately late 2nd/early 3rd trimester of human gestation with 
regard to brain development (Rice and Barone, 2000). Due to the neurotropic property 
of the A/WSN/33 strain of influenza virus, a peripheral infection targets the brain and 
elicits an immune response. The dosage of the influenza A virus (i.e. 2,400 plaque-
forming units suspended in 30 µL) was based on pilot studies assessed by 
experimenters at the Department of Neuroscience, Karolinska Institutet. The mice were 
monitored daily following the infection. Signs of severe infection symptoms, such as 
reduced weight gain, resulted in immediate sacrificing and exclusion from the study, 
according to institutional guidelines.  
 
3.3.2 L-kynurenine treatment of mice 
To mimic a transient elevation of brain KYNA in neonatal mice, the precursor  
L-kynurenine was injected i.p. daily from P7 to P16, every 12th hour (paper III). Pilot 
studies demonstrated a two-fold elevation of brain KYNA concentrations following this 
treatment compared with brain concentrations in control mice injected with saline in a 
similar manner.  
 
 
3.4 INFLUENZA A/WSN/33 VIRUS INFECTION OF PRIMARY CELL 
CULTURES 
In paper I, primary cell cultures of neurons or glial cells were established from mouse 
brains. The cultures were infected with influenza A/WSN/33 virus. The choice of 
primary cell cultures instead of cell lines was based on the fact that immortalized cell 
lines, often derived from cancerous tissue, may not have the same characteristics as 
normal cells, for example regarding gene expression. Thus, primary cell cultures may 
be more likely than cell lines to reflect in vivo cell properties. However, one must bear 
in mind that these cells grow in an environment detached from physiological events in 
the brain. In our study, hippocampal neuron cultures and cerebral cortex glial cell 
cultures were prepared from C57BL/6 mice embryos sampled at embryotic day (E) 16 
(day of vaginal plug = E0). Hippocampus and cortex were dissected, collected and 
dissociated in trypsin, which degrades the extracellular matrix. Neurons were cultured 
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in Neurobasal medium (optimal for prenatal and embryonic neuronal cells growth) with 
B-27 Serum-Free Supplement, which reduces glial cell growth. The cells were able to 
differentiate for seven days in the culture before the experiment, resulting in a nearly 
pure neuron culture with less than 2.5% glial cells, and were denoted hippocampal 
neuron cultures. Cerebral cortex cells were cultured in Dulbecco’s Modified Eagle’s 
Medium/F-12 (1:1) medium with 10% serum and G-5 Supplement, designed for glial 
cell growth (astrocytes). The cortical cultures were allowed 2-3 passages prior to the 
experiment. At this point, the majority of these proliferating cells stained positive for 
the astrocyte marker glial fibrillary acidic protein (GFAP) (Nygård, 2007), and were 
denoted cerebral cortex glial cell cultures. 
 
Prior to the infection, the cell cultures were washed twice with Modified Eagle’s 
Medium. Influenza A/WSN/33 virus was diluted in Modified Eagle’s Medium and 
added to the cultures in 0.5 multiples of infection, i.e. one virus particle per two cells. 
The cultures were carefully agitated every 10 min to evenly distribute the virus in the 
cell cultures. Incubation temperature was 37 °C. Virus supernatants were removed after 
one hour and complete cell culture medium was added. The infection in cerebral cortex 
glial cell cultures and hippocampal neuron cultures was allowed to proceed for 24 
hours and 48 hours, respectively, before the cells were harvested. 
 
3.5 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 
The high-performance liquid chromatography (HPLC) system is used for identification, 
quantification and separation of compounds in liquid samples using a two-phase 
system. In paper I, II, III and V an isocratic reversed-phase HPLC system was used to 
analyze endogenous KYNA and/or kynurenine. Samples of brain and spleen tissue 
were homogenized in perchloric acid, sodium hydrogensulfite, ethylenediaminetetra-
acetic acid (EDTA) prior to the HPLC analyses (paper I, II and III). CSF samples 
were analyzed unprocessed (paper V). 
 
Separate samples was injected into the HPLC apparatus and mixed with a mobile phase 
of acetonitrile, used as a moderately polar solvent of the samples. In reversed-phase 
HPLC, a constant pH is necessary to stabilize the hydrophobicity of the substance to be 
analyzed. Therefore, the mobile phase also included a buffer solution of sodium acetate 
with pH 6.2. The solution is pumped through the system and when it reaches the 
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stationary phase of porous silica beads within the column, the molecules bind to the 
non-polar beads. Depending on the polarity of the molecules, the time they take passing 
through the column will differ, generating separation by explicit retention time. 
Retention time is longer for less polar molecules. The HPLC system was connected to a 
fluorescence detector with an excitation wavelength of 344 nm and an emission 
wavelength of 398 nm for KYNA analysis, and to a UV-VIS detector operating at 365 
nm for kynurenine analysis. The eluate of the column was mixed with zinc acetate, 
forming a zinc complex required for the fluorescence/UV-VIS detection. Identification 
and quantification of KYNA or kynurenine was achieved by performing a scatter plot 
of the standard solution at different concentrations, relating the peak altitudes in the 
chromatogram to the respectively standard solution concentrations. These plots were 
subsequently used to obtain the concentration of KYNA or kynurenine in the samples.  
 
 
3.6 IMMUNOFLUORESCENT LABELING OF T CELLS 
Immunofluorescence is a type of immunohistochemistry that uses fluorescence to 
visualize the distribution of small molecules in biological tissue. In paper I this method 
was used to investigate the putative invasion of T cells in infected mouse brains. 
Coronal sections of fresh frozen hemispheres were incubated at 4 °C with either rat 
anti-mouse CD4 antibodies or rat anti-mouse CD8a antibodies for 24 hours. A 
secondary donkey anti-rat IgG antibody conjugated to the fluorophore rhodamine red 
was thereafter applied at room temperature for 60 min. Photomicrographs were taken 
with a fluorescent microscope. As positive control, sections of mouse thymus were 
handled correspondingly, and as negative control only secondary antibody on mouse 
brain sections was used (Asp, 2009).  
 
 
3.7 RNA ISOLATION AND REAL-TIME PCR  
Real-time polymerase chain reaction (PCR) was performed to analyze gene expression, 
i.e. mRNA transcripts, in tissue or cell samples (paper I and II). Prior to the gene 
expression analyses, total RNA from the samples was purified with Qiagen RNeasy 
Mini kit. Residual genomic DNA was eliminated from the RNA using DNase I 
(Invitrogen). The isolated total RNA, including viral RNA and 1-5% mRNA, was 
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thereafter converted to complementary DNA (cDNA) by using the reverse transcriptase 
Superscript II and random hexamer primers (Invitrogen).  
 
With the PCR method it is possible to selectively amplify a specific DNA sequence 
from a very limited starting material. Real-time PCR allows detection of the product as 
it is being generated, i.e. in real time. This amplification process employs thermal 
cycles of repeated heating and cooling. The reaction mix consists of two 
oligonucleotide primers designed to hybridize with the forward or reverse strand of the 
sequence to be amplified, deoxynucleoside triphosphate nucleotides (dATP, dCTP, 
dGTP, dTTP), and a thermostable DNA polymerase synthesizing the novel DNA 
strand. For every thermal cycle the product amount is doubled.  
 
In this thesis, two types of fluorescent detection chemistries were applied: TaqMan® 
and SYBR® Green. The TaqMan assay was only used to analyze the expression of the 
endogenous control gene Gapdh (encoding glyceraldehyde-3-phosphate dehydro-
genase, GAPDH). For all other gene expression levels, SYBR® Green was used. The 
TaqMan technique depends on the correct hybridization of both primers and a dye-
labeled probe to emit the fluorescent signal, while SYBR Green binds to all double 
stranded DNA generated in the PCR amplification. Thus, a more specific binding to the 
target sequence is achieved when using the TaqMan assay. The limitation of SYBR 
Green assay can however be compensated for by observing the melting temperature for 
the target sequence, as well as by cloning and sequencing the PCR product, thus 
verifying that the primers bind to the correct target. 
 
In our studies, the levels of transcripts are presented as relative changes obtained by 
using the formula 2-ΔΔCt (Livak and Schmittgen, 2001). The absolute transcript copy 
number was not analyzed. Explained briefly, the cycle threshold (Ct) refers to the 
number of thermal cycles required for a certain DNA sequence to reach an arbitrary 
threshold for the fluorescent signal. The delta Ct-value (ΔCt) is obtained by the 
difference in Ct-numbers between the target sequence and an endogenous control 
sequence, presumably not affected by the experimental treatment. This compensates for 
(or normalizes) any differences in the amount of cDNA that was synthesized or in the 
amount of cDNA that was added to the PCR reaction. For all gene expression analyses 
included in this thesis, transcripts encoding GAPDH were verified as valid endogenous 
Methodological Considerations 
 
 38 
controls. The delta delta Ct-value (ΔΔCt) is the difference in ΔCt between separate 
samples, for instance between virus-infected and non-infected samples. The change in 
expression levels of a target gene was thus first normalized to the endogenous control 
Gapdh and then presented as a fold change relative to the untreated control sample. 
 
 
3.8 BEHAVIORAL TESTS 
The behavioral tests were performed in adult mice to investigate potential long-term 
behavioral effects similar to schizophrenia characteristics, following a CNS disturbance 
in neonatal life induced by virus infection or by elevated brain KYNA as described 
above. Behavioral tests were performed in paper II (PPI) and paper III (PPI and 
locomotor activity). 
 
To avoid potential confounds when performing animal behavioral experiments, various 
issues need to be considered regarding handling of the animals, circadian rhythm, 
hormonal cycles, body weight, and interfering external noise or smell, etc. In our 
studies, all mice were handled by a small number of persons, including the operator 
performing the actual behavioral experiments. Environmental factors such as 
temperature and humidity in colony rooms, light/dark cycle, and testing time of day 
were kept constant throughout the course of the studies. All comparative mice (treated 
vs. controls) were maintained under the same laboratory conditions. Only male mice 
were included in these studies, and all comparisons were made within genotypes.  
 
 
3.8.1 Prepulse inhibition 
PPI of an acoustic startle reflex is a cross-species translational model widely used in the 
fields of behavioral neuroscience and neuropsychopharmacology. It is an operational 
measure of sensorimotor gating, i.e. the filtering of environmental inputs, and is defined 
as the ability of a weak non-startling stimulus (the prepulse) to reduce the response of a 
subsequent startling stimulus (the pulse) presented 30 to 500 ms after the prepulse 
(Hoffman and Ison, 1980). Although considerable evidence has established that 
patients with schizophrenia have deficiencies in sensorimotor gating (McGhie and 
Chapman, 1961), as measured by PPI (Braff et al., 2001; Swerdlow et al., 2008), the 
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model is not a tool for schizophrenia diagnosis. PPI deficiencies are observed in many 
other disorders such as obsessive-compulsive disorder, Huntington’s disease, 
Tourette’s syndrome and bipolar disorder (Braff et al., 2001; Perry et al., 2001). 
Nevertheless, the PPI test in rodents serves as a robust and reliable animal model 
representing the pre-attentive gating deficits in schizophrenia due to its demonstrated 
face, predictive, and construct validity (Swerdlow et al., 1994).  
 
One of the core characteristics in patients with schizophrenia is difficulty in sustained 
attention. This aspect of information processing has been suggested to be closely 
associated with working memory (Awh et al., 2006), an acknowledged measure of 
cognition. In rodents, however, PPI does not reveal any information about higher 
cognitive functions. Rather, the translational PPI test of mice and rats is a useful tool 
for evaluating animal models that are relevant to schizophrenia (Swerdlow et al., 2008). 
In our studies, PPI was used to assess neonatal CNS virus infection in the mouse as a 
model for development of schizophrenia.  
 
For startle and PPI testing in our studies, the mouse was placed in a Plexiglas cylinder 
(3.7 cm in diameter), inside a ventilated and sound-attenuating startle chamber (35 x 33 
x 33 cm; San Diego Instruments, San Diego, CA). Two chambers were used 
simultaneously, allowing one treated mouse and one control mouse to be tested at the 
same time. A loudspeaker placed inside the chamber provided a broadband background 
noise of 65 dB as well as the acoustic stimuli, controlled by a standard computer. 
Sudden movements by the mouse were detected by a piezoelectric accelerometer 
attached below the cylinder, and registered by the Startle software.  
 
The session used in our studies was designed to fully characterize the startle and PPI 
phenotype based on previous reports of isolation-reared C57BL/6 mice (Varty et al., 
2006). Briefly described, the session consisted of a five-minute acclimatization period 
to the background noise, which was continuous throughout the session, followed by 
three different test blocks (Table 1): A variable stimulus intensity block (to measure 
the startle threshold), a variable prepulse intensity block, and a variable interstimulus 
interval (ISI) block.  
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To obtain percent acoustic PPI from the variable prepulse intensity block and the 
variable ISI block, the following formula was used: 100 - ((average startle of PREPULSE 
+ PULSE trial) / (average startle of PULSE ALONE trial)) x 100              
 
Table 1. Overview of the test session build-up. Throughout the session, the trial types were presented in a 
pseudo-random order with an average inter-trial interval of 15 seconds. 
BLOCK	   TRIALS	  
PRESENTATION	  
OF	  TRIALS	  
Variable	  stimulus	  
intensity	  block	  
40-­‐ms	  startle	  pulse	  of	  	  
80,	  90,	  100,	  110	  and	  120	  dB	  (PULSE	  ALONE)	  
4	  times	  each	  
Variable	  prepulse	  
intensity	  block	  
40-­‐ms	  startle	  pulse	  of	  120	  dB	  (PULSE	  ALONE)	   12	  times	  
20-­‐ms	  of	  69,	  73	  or	  81	  dB	  followed	  100-­‐ms	  later	  	  
by	  120	  dB	  (PREPULSE	  +	  PULSE)	  
10	  times	  each	  
Variable	  interstimulus	  
interval	  block	  
40-­‐ms	  startle	  pulse	  of	  120	  dB	  (PULSE	  ALONE)	   8	  times	  
20-­‐ms	  of	  73	  dB	  followed	  25-­‐ms,	  50-­‐ms,	  100-­‐ms,	  	  
200-­‐ms	  or	  500-­‐ms	  later	  by	  120	  dB	  (PREPULSE	  +	  
PULSE)	  
4	  times	  each	  
 
 
3.8.2 Open field locomotor activity 
The open field arena is commonly used to study both basal and drug-induced locomotor 
activity in rodents. Acute administration of amphetamine enhances locomotor activity. 
Amphetamine stimulates extracellular dopamine release, and may also display 
psychomimetic effects in humans. Patients with schizophrenia show a hyper-
responsiveness to this drug, by demonstrating an excessive striatal dopamine release, 
and the amount of abnormal dopamine release correlates with the positive symptoms 
(Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998). The potentiated 
increase of locomotor response to acute administration of D-amphetamine in mice has 
therefore been used to model schizophrenia.  
 
The open field arena (50 cm x 50 cm) was surrounded by 21.6 cm high walls of 
Plexiglas, enclosed in a solid and sound-dampened chamber. To detect movement of 
the mouse, the boxes were equipped with photocell beams. In our studies horizontal 
activity, defined as total counts of crossed photocells (computer recorded, collected in 
five-minute blocks), was analyzed. All mice were habituated during three sessions of 
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60 minutes, 24 hours apart. Basal horizontal activity was assessed by the last 
habituation session (0-60 min). D-amphetamine or vehicle was thereafter immediately 
injected i.p., followed by a test session of 90 minutes (60-150 min). For statistical 
analyses of the test session, the last recorded count of the basal horizontal activity (55-
60 min) was set to represent baseline activity.  
 
 
3.9 HUMAN SAMPLES 
In paper IV and V human samples originating from Sweden, Denmark and Norway 
were analyzed. These studies was approved by the local ethics committees including 
the Danish Scientific Committees, the Danish Data Protection Agency, the Norwegian 
Scientific-Ethical Committees, the Norwegian Data Protection Agency, the Ethical 
Committee of the Karolinska Hospital, the Stockholm Regional Ethical Committee and 
the Swedish Data Inspection Board (Jönsson et al., 2009). All participants had given 
informed consent prior to inclusion in the studies, in line with the Declaration of 
Helsinki. 
 
The patients included in our studies were recruited from psychiatric departments in the 
local regions of Stockholm, Oslo and Copenhagen, and were clinically diagnosed 
according to the DSM-III-R/DSM-IV or the ICD-10. Healthy control subjects were 
included based on statements that they felt completely healthy or on interviews 
asserting that they were not suffering from any severe psychiatric disorder. All 
participants were Caucasians. In paper IV, patients with schizophrenia, schizoaffective 
disorder or schizophreniform disorder were compared with unrelated, age-matched 
controls. In paper V, only patients with schizophrenia (drug-naïve, drug-free or drug-
treated) were included as affected individuals. A more detailed description of the 
participants included in these case-control association studies has been summarized in 
Jönsson et al. 2009.  
 
 
3.10 GENOTYPING OF HUMAN DNA SAMPLES  
Genomic DNA was isolated from whole blood, and the genotyping of SNPs were 
performed by the SNP technology platform in Uppsala, Sweden, using the Illumina 
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BeadStation 500GX and the 1536-plex Illumina Golden Gate assay (Illumina Inc.). 
Briefly explained, this bead array technology depends on allele-specific primers 
together with a locus-specific probe that both hybridize to the genomic DNA 
(immobilized on solid support). The fluorescent signal was then obtained from 
additional allele-specific labeled primers (www.genotyping.se). Since the genotyping 
was performed as contract research, further presentation of this method is not given. 
 
In the association studies included in this thesis, polymorphisms in the KMO gene were 
investigated by genotyping 15 SNPs. These SNPs were selected in 2007 during my 
degree project from the Caucasian database of the International HapMap Project 
(www.hapmap.org) and the non-public RAVEN database (searching SNPs at potential 
transcription factor binding sites). LD-blocks were obtained with Haploview 4.1, and 
SNPs were selected within and between the gene LD-blocks, including non-
synonymous SNPs as well as tagSNPs representing a haplotype frequency > 5%. Ten 
of the 15 polymorphisms were genotyped in HapMap Caucasian samples (release 27) 
linked to the variation of an additional 40 of the 63 KMO HapMap SNPs genotyped 
within the region that was analyzed in our studies (R2 > 0.85 Haploview 4.1). Thus, the 
selected SNPs represented at least 79% of the total KMO SNPs. Prior to the analyses, 
the SNP genotype frequencies in the control sample were tested for Hardy-Weinberg 
equilibrium.
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4 RESULTS AND DISCUSSION 
 
4.1 INFLUENZA VIRUS INFECTION OF MICE IN VITRO AND IN VIVO: 
INDUCTION OF THE KYNURENINE PATHWAY 
Disturbances during development of the human brain are suggested to contribute to the 
pathogenesis of schizophrenia (Murray and Lewis, 1987; Weinberger, 1987). As a 
potential mechanism in this regard, early-life hypofunction in glutamatergic NMDA 
receptor signaling has been suggested (Olney et al., 1999; Coyle, 2006). Accordingly, 
neonatal blockade of the NMDA receptor causes deficits in sensorimotor gating and 
increases locomotor activity in adult rats (Harris et al., 2003). Furthermore, mice 
expressing very low levels of the essential NR1 subunit of the NMDA receptor display 
behavioral aberrations that are proposed to model schizophrenia (Mohn et al., 1999). 
These results raise the possibility that blockade of NMDA receptors through elevated 
levels of endogenous KYNA in early life may induce neurodevelopmental 
impairments. Tryptophan breakdown via the kynurenine pathway is induced by various 
infections of the CNS (see section 1.3.2), and can be considered as part of the host 
innate immune response (King and Thomas, 2007). Indeed, early-life infections are 
recognized as a risk factor for the development of psychotic illness, including 
schizophrenia, later in life (Brown et al., 2000a; Buka et al., 2001a; Mortensen et al., 
2007; Dalman et al., 2008).  
 
In our studies (paper I-III), the impact of a mouse-adapted neurotropic strain of 
influenza A virus infection (WSN/33) on the kynurenine pathway during early life was 
studied in vitro and in vivo. With the developmental theory of schizophrenia in mind, 
long-term behavioral effects of the neonatal infection or kynurenine pathway induction 
were investigated in adult life. 
 
 
4.1.1 Effects of the virus infection in mouse brain cell cultures 
In paper I, primary cultures of hippocampal neurons or cortical glial cells were 
infected with influenza A/WSN/33 virus. The effects on gene expression of the virus 
infection in vitro are shown in Figure 2. In both types of cultures, the virus infection 
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induced robust increases in the levels of transcripts from the genes encoding IDO and 
TDO, the enzymes metabolizing tryptophan in the first step of the kynurenine pathway. 
With regard to transcripts encoding IDO, this effect is potentially mediated by pro-
inflammatory cytokines produced by the infected cells (Ronni et al., 1997; Guillemin et 
al., 2001a; Guillemin et al., 2005b), or alternatively by a direct effect of viral proteins 
(Boasso et al., 2007). Notably, IDO has been suggested to be an important immune-
controlling enzyme (King and Thomas, 2007). However, the gene encoding TDO 
(Tdo2) has not been considered to be regulated by inflammatory stimuli (Saito et al., 
1992; Saito et al., 1993; Heyes et al., 1998), although TDO induction take place in 
placental tissue during intrauterine bacterial infections (Manuelpillai et al., 2003). 
 
 
Figure 2. Levels of transcripts in hippocampal neuron cultures and cortical glial cell cultures. Dots 
represent biological replicates from two separate experiments. The levels of transcripts from the genes 
Indo (encoding IDO), Tdo2 (encoding TDO), Ccbl1 (encoding KAT 1), Aadat (encoding KAT 2), Ccbl2 
(encoding KAT 3), Got2 (encoding mitAAT), Kmo (encoding KMO), Kynu (encoding KYNU), Haao 
(encoding HAAO) and Qprt (encoding QPRT) in primary hippocampal neuron cultures (A) and primary 
cortical glial cell cultures (B). The levels of transcripts in influenza A/WSN/33 virus-infected cultures (+) 
are relative to those observed in control cultures (-). The horizontal lines indicate median values.  
** p < 0.01, *** p < 0.001. Mann Whitney U test. 
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Large relative increases in the levels of transcripts encoding KMO, the enzyme 
converting kynurenine towards the neurotoxin QUIN, were observed in both 
hippocampal neuron cultures and cortical glial cell cultures following infection. The 
two cell culture types appeared diversified in their response to infection with regard to 
transcripts encoding KYNU and QPRT, as these transcript levels were only induced in 
the neuronal cultures. This finding is in line with previous reports (Heyes et al., 1997a; 
Guillemin et al., 2005b) and supports the notion that production of various metabolites 
in the kynurenine pathway is dependent on specific cell types. In light of the recently 
proposed link between the levels of transcripts encoding KYNU and KMO and the 
capacity to produce QUIN (Guillemin et al., 2007), our findings suggest further 
metabolism of kynurenine towards QUIN, at least in infected neuronal cultures. 
However, measurements of other metabolites downstream kynurenine in the pathway 
were not performed here. With regard to the kynurenine metabolism into KYNA, four 
KAT enzymes was analyzed. Mitochondrial aspartate aminotransferase (mitAAT, 
identical to glutamate oxaloacetate transaminase 2 encoded by the gene Got2) was 
included in our analyses, as it was recently suggested to account for a significant 
proportion of total brain KAT activity in mice (Guidetti et al., 2007). However, none of 
the transcripts encoding the KAT enzymes in the two cultures was elevated following 
virus infection. The levels of transcripts encoding KAT 3 were lower in the infected 
hippocampal neuron cultures as compared with controls, and in glial cell cultures, 
levels of transcripts encoding KAT 1 and mitAAT were reduced in the infected cultures 
compared with controls. It should be noted that the standard culture conditions 
employed here may account for some of the differences between the two cultures and 
thus further studies are needed to address such issues. 
 
In summary, our results from studies of cortical glial cell or hippocampal neuron 
cultures in vitro demonstrate that a virus infection induces the kynurenine pathway, 
involving a robust increase in levels of the transcripts encoding IDO and TDO, 
enzymes regulating the first and rate-limiting reaction of KYNA production. These 
observations further emphasis a role of the kynurenine pathway in immune responses 
of the brain.  
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4.1.2 Early-life effects of neonatal virus infection in wild-type and Tap1-/- 
mouse brain 
In the studies in vivo, mice were infected neonatally at P3 or P4 and the brains and 
spleens were harvested at P7, P13 or P24. In the brains of infected wild-type mice 
(paper I), the highest levels of viral RNA were observed at P7, and at P24 the viral 
RNA was detected at low levels in all but one animal. The levels of viral RNA in the 
brains far exceeded those observed in spleens (10- to 1000-fold) at all time-points 
investigated, and the virus was cleared from the spleens more rapidly than from the 
brains. Invasion of CD4+ and CD8+ T cells, both important mediators of virus clearance 
from infected brains (Stevenson et al., 1997a), was detected in the brains of infected 
mice at P13, but not at P7. At P24, the number of infiltrating T cells had decreased 
considerably.  
 
The effects on gene expression by the neonatal infection of the wild-type mice are 
shown in Figure 3. Already at P7, activation of tryptophan degradation was indicated 
by altered expression of several of the genes in the kynurenine pathway. Based on our 
results in vitro and on other reports (Guillemin et al., 2001b; Guillemin et al., 2007), 
see (Moffett and Namboodiri, 2003), it is likely that the response in vivo observed here 
involves several cell types including neurons, astrocytes and microglia. The finding that 
gene expression was induced at P7 although no infiltrating T cells were observed at this 
time-point may suggest that the activation of tryptophan degradation along the 
kynurenine pathway contributes to a limitation of viral replication, as initially proposed 
by Pfefferkorn (1984). However, several kynurenine pathway metabolites have 
previously been reported to suppress T cell proliferation, see (Moffett and Namboodiri, 
2003), which may be particularly important in the brain with its limited regenerative 
capacity. In support of this latter view, our results showed that the infiltration of T cells 
at P13 was concomitant with a sustained elevation of transcripts encoding enzymes 
metabolizing kynurenine towards the synthesis of QUIN, i.e. KMO, KYNU, and 
HAAO, and the additional induction of the gene encoding QPRT. Present data does not 
ascertain whether this gene expression response is mediated by the invading T cells 
themselves or by the brain parenchyma to limit the actions of potentially destructive T 
cells.  
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Figure 3. Levels of transcripts in mouse brain. Dots represent individual mice from two separate 
experiments. The levels of transcripts from the genes Indo (encoding IDO), Tdo2 (encoding TDO), Ccbl1 
(encoding KAT 1), Aadat (encoding KAT 2), Ccbl2 (encoding KAT 3), Got2 (encoding mitAAT), Kmo 
(encoding KMO), Kynu (encoding KYNU), Haao (encoding HAAO) and Qprt (encoding QPRT) in 
brains at P7 (A) and at P13 (B) following intraperitoneal injection with 2,400 plaque-forming units of 
influenza A/WSN/33 virus (+) or vehicle (-) on P3 or P4. The levels of transcripts in infected brains are 
relative to those observed in controls. The horizontal lines indicate median values.  
* p < 0.05, ** p < 0.01, *** p < 0.001. Mann Whitney U test. 
 
 
Induction of the kynurenine pathway was accompanied by a transient increase in brain 
KYNA concentration, significantly elevated at P13 (Figure 4). Neither levels of 
transcripts encoding the enzymes IDO/TDO nor those encoding the KAT enzymes 
were elevated at this time-point. Thus, induction of the genes encoding the KAT 
enzymes did not appear to be necessary for increased KYNA formation. This is in line 
with previous experimental studies where poliovirus-infected rhesus macaques showed 
increased CSF KYNA despite no changes in KAT activity (Heyes et al., 1993). Indeed, 
recent studies investigating the activities of enzymes in the kynurenine pathway in the 
brains of patients with schizophrenia found unchanged activity of KAT, even though 
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brain KYNA was elevated (Sathyasaikumar et al., 2010). The elevated levels of mice 
brain KYNA in the present study may be related to increased levels of transcripts 
encoding IDO at earlier time-points (as indicated by increased levels of these 
transcripts at P7). A slight, but non-significant, increase of these transcripts was 
observed at P13, possibly contributing to the KYNA elevation. One might also 
speculate if the elevation of brain KYNA could be related to an increased synthesis of 
peripheral kynurenine, which readily crosses the BBB (Fukui et al., 1991). Indeed, 
systemic administration of L-kynurenine in rats is associated with a marked elevation in 
brain KYNA (Erhardt and Engberg, 2002; Linderholm et al., 2007). Analyses of 
spleens from the infected mice did not show elevation of TDO/IDO transcripts or of 
kynurenine or KYNA concentrations at any of the measured time-points. However, a 
trend towards increased levels of IDO transcripts at P7 and P13, as well as of 
kynurenine at these time-pionts, was observer, but without statistical significance. 
Thus, increased concentration of peripheral kynurenine should not be disregarded in 
contributing to the elevated KYNA concentration in the mouse brain following the 
influenza infection. At P24, none of the transcripts that were elevated at P13, i.e. those 
encoding KMO, KYNU, HAAO and QPRT, were altered. 
 
 
  
 
 
 
 
 
 
Figure 4. Levels of KYNA in mouse brain at P7, P13 and P24 following 
intraperitoneal injection with 2,400 plaque-forming units of influenza 
A/WSN/33 virus (+) or with phosphate buffered saline (-) on P3-4. Dots 
represent individual mice from two separate experiments. The horizontal lines 
indicate median values. ** p < 0.01. Mann Whitney U test. 
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In paper II, neonatally infected Tap1-/- mice, with reduced expression of MHC class I 
molecules and thus lacking functional CD8+ T cells (Van Kaer et al., 1992), were used. 
In a previous report employing the same infection model as used in our studies, an 
increased expression of glial markers in the brain parenchyma was observed at P24 in 
Tap1-/-, but not in wild-type mice, following the neonatal virus infection (Asp et al., 
2009). Thus, a more pronounced innate immune response in these immunodeficient 
mice was proposed. As compared with wild-type mice, the absence of invading CD8+ T 
cells did however not affect virus replication, distribution or rates of clearance in these 
mice. Nor did the survival rate between the two strains differ (Asp et al., 2009). 
 
Following virus infection of neonatal Tap1-/- mice, the transcript levels of several 
enzymes of the kynurenine pathway were altered at all measured time-points, i.e. P7, 
P13 and P24 (Figure 5). The changes in gene expression were accompanied by a 
transient increase in the levels of KYNA in the brain parenchyma at P13 (Figure 6). 
Thus, increased tryptophan degradation via induction of the kynurenine pathway in the 
Tap1-/- mice brains is largely in agreement with our previous findings in wild-type 
mice. A notable difference, however, was the consistent elevation of transcripts 
encoding IDO in the Tap1-/- mice brains throughout all time-points investigated. Levels 
of transcripts encoding mitAAT were not altered in virus-infected mice at any of the 
investigated time-points. Decreased levels of transcripts encoding KAT 2 (at P7 and 
P13), and increased levels of transcripts encoding KAT 3 (at P13) were observed. 
However, as indicated by the results in paper I, the influence of a transcriptional 
changes of the KAT enzymes seems to be of minor importance for the formation of 
KYNA. Rather, the availability of kynurenine should determine KYNA concentrations. 
As was also observed in our studies in vitro, the results in vivo indicate further 
metabolism of kynurenine into 3-HK and other downstreem metabolites of the 
kynurenine pathway. However, measurements of these metabolites were not performed 
in our studies.  
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Figure 5. Levels of transcripts in brains of Tap1-/- mice. Dots represent individual mice. The levels of 
transcripts from the genes Indo (encoding IDO), Tdo2 (encoding TDO), Ccbl1 (encoding KAT 1), Aadat 
(encoding KAT 2), Ccbl2 (encoding KAT 3), Got2 (encoding mitAAT), Kmo (encoding KMO), Kynu 
(encoding KYNU), Haao (encoding HAAO), and Qprt (encoding QPRT) in brains at P7 (a), at P13 (b), 
and at P24 (c) following intraperitoneal injection with 2,400 plaque-forming units of influenza 
A/WSN/33 virus (+) or phosphate buffered saline (-) on P3 or P4. The levels of transcripts in virus-
infected brains are relative to those observed in uninfected brains. The horizontal lines indicate median 
values. * p < 0.05, ** p < 0.01, *** p < 0.001. Mann Whitney U test. 
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In paper I, no evidence of an activated brain kynurenine pathway was observed at P24 
in infected wild-type mice. The increased levels of transcripts encoding IDO, KYNU, 
and HAAO observed in the Tap1-/- mice at this time-point (paper II), suggest a more 
persistent induction of the kynurenine pathway in these mice. Although the cellular 
origins of these transcripts were not further investigated, IDO, KYNU, and HAAO can 
all be expressed by cells in the brain parenchyma, such as astrocytes, microglia and 
neurons, as well as by invading cells, such as macrophages (Alberati-Giani et al., 1996; 
Guillemin et al., 2001b; Guillemin et al., 2003b; Guillemin et al., 2007). Our 
observations thus provide further support for a more pronounced innate immune 
response in the brains of Tap1-/- mice than in wild-type mice following a neonatal virus 
infection, as also proposed by Asp et al. (2009). The difference in innate immune 
response between the two genotypes may be related to the absence of functional CD8+ 
T cells in the Tap1-/- mice. CD8+ and CD4+ T cells have been reported to be critically 
important in down-regulating the systemic innate immune response also in young mice 
(Zhao et al., 2008).  
 
Figure 6. Levels of KYNA in brains of Tap1-/- mice at P7, P13 and P24 
following intraperitoneal injection with 2,400 plaque-forming units of 
influenza A/WSN/33 virus (+) or phosphate buffered saline (-) on P3 or 
P4. Dots represent individual mice. The horizontal lines indicate median 
values. ** p < 0.01. Mann Whitney U test. 
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In summary, the studies on wild-type and Tap1-/- mice reveal that a neonatal systemic 
infection targeting the brain stimulates tryptophan degradation via the kynurenine 
pathway in early life. The latter group of genetically vulnerable mice appeared to be 
more sensitive to the CNS infection, as they showed a more persistent induction. As the 
kynurenine pathway induction also included elevated levels of the NMDA receptor 
antagonist KYNA, these early-life disturbances might disrupt glutamatergic signaling 
in the developing brain, a condition proposed to occur in schizophrenia. 
 
 
4.1.3 Behavioral effects in adult mice following neonatal treatment 
Frequent animal studies show an association between early-life infections and 
persistent behavioral effects related to both cognitive and emotional domains, as well as 
disrupted sensorimotor gating in adult animals (see section 1.2.1.1). To assess long-
term behavioral effects following the neonatal infection and the subsequent kynurenine 
pathway induction, we analyzed putative behavioral deficiencies in adult mice by 
utilizing the PPI test (wild-type and Tap1-/- mice) and by evaluating locomotor activity 
(wild-type mice only), following a challenge with D-amphetamine (5 mg/kg). Separate 
sets of mice were treated with L-kynurenine 200 mg/kg twice a day i.p. at P7-16. This 
treatment resulted in a two-fold elevation of brain KYNA at the end of treatment, thus 
mimicking the induction of the kynurenine pathway and the transient accumulation of 
KYNA in early life following a neonatal influenza infection. Neonatally L-kynurenine-
treated mice were subsequently assessed in adulthood with regard to PPI and locomotor 
activity. No statistical analyses were performed between the different sets of mice (i.e. 
influenza virus-infected wild-type mice, influenza virus-infected Tap1-/- mice and  
L-kynurenine-treated mice). Table 2 shows the whole brain KYNA concentrations in 
adult mice, measured after the behavior assessments. 
 
 
 
 
 
 
 
Maria Holtze 
 
 53 
Table 2. Whole brain KYNA concentration in adult C57BL/6 mice.  
Neonatal treatment KYNA (mean ±  SEM) Significance difference 
Influenza A virus, WT (n = 8) 2.03 ± 0.20 nM 
p = 0.17 
Uninfected, WT (n = 10) 1.69 ± 0.16 nM  
Influenza A virus, TAP (n = 10) 4.20 ± 1.74 nM 
p = 0.54 
Uninfected, TAP (n = 14) 2.98 ± 0.53 nM 
L-kynurenine (n = 8) 5.37 ± 1.10 nM 
p = 0.37 
Control (n = 9) 4.06 ± 0.51 nM 
WT: wild-type mice, TAP: Tap1-/- mice. 
 
4.1.3.1 Prepulse inhibition  
Sensorimotor gating was assessed in adult animals by performing the PPI test on 
neonatally infected wild-type and Tap1-/- mice as well as on neonatally L-kynurenine-
treated mice (paper II and III). 
 
Wild-type mice neonatally infected at P3 or P4 with the neurotropic influenza 
A/WSN/33 virus did not differ from uninfected mice with regard to PPI in any of the 
test blocks performed. 
 
In contrast, virus-infected Tap1-/- mice displayed impaired PPI in the varied ISI block of 
the test session, as indicated by a main effect of virus infection (F(1,26) = 5.67, p < 
0.05; Figure 7a) without any interaction between virus infection and ISI. The post hoc 
test revealed a decrease in PPI in virus-infected mice at the 200 ms ISI (p < 0.05). 
Startle magnitude to the P120 trials in the varied ISI blocks did not differ between the 
groups (Figure 7b). In the varied prepulse intensity block, there was no difference 
between virus-infected and uninfected Tap1-/- mice. There was, however, a trend 
towards a higher startle threshold response in the virus-infected Tap1-/- mice compared 
with uninfected Tap1-/- mice (F(1,26) = 3.81, p = 0.062). Since no interaction between 
acoustic stimuli and virus infection was obtained, the groups should not differ in their 
threshold for startle response. 
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The finding of a reduced PPI in adult Tap1-/- mice, but not in adult wild-type mice, is in 
line with a previous study, employing the same infection model as used in the present 
studies, reporting deficits in working memory and increased anxiety in adult Tap1-/- 
mice, but not in adult wild-type mice (Asp et al., 2009). Thus, an interaction between 
the Tap1 gene and neonatal influenza infection is indicated. In humans, genetic 
polymorphisms in TAP1 have been suggested to associate with susceptibility to virus 
infection (Xu et al., 2007), and possibly with schizophrenia (Fellerhoff and Wank, 
2009). 
 
Mice subjected to a subchronic elevation of endogenous brain KYNA in early life, 
displayed a subtle PPI impairment in the ISI-block as indicated by an interaction 
between L-kynurenine treatment and ISI (F(4,64) = 3.37, p < 0.05; Figure 8A). 
However, no main effect of neonatal L-kynurenine treatment was observed. Post hoc 
analysis revealed a significant effect of L-kynurenine treatment at the 500 ms ISI (p < 
0.01). No difference was observed in startle magnitude to the P120 trials in this block 
between the groups (Figure 8B). In the varied prepulse intensity block, there was no 
main effect on L-kynurenine treatment or any interaction between L-kynurenine 
Figure 7. PPI (a) and startle magnitude (b) in uninfected (n = 16) and 
influenza A/WSN/33 virus-infected (n = 12) Tap1-/- mice at 5-6 months of 
age, during the varied ISI block of the startle session. # p < 0.05, main effect 
of virus infection on PPI during the varied ISI block. * p < 0.05, statistically 
different from respective uninfected mice, Tukey’s post hoc comparison. 
Data are presented as mean + SEM. 
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treatment and prepulse intensity. No difference in startle threshold response was 
obtained between the two groups. 
 
 
 
 
 
 
 
 
 
 
Acutely increased brain KYNA in adult rats has previously been associated with 
disruptions in PPI. Based on this, brain KYNA was proposed as an endogenous 
modulator of sensorimotor gating (Erhardt et al., 2004). Notably though, in the present 
study we did not detect any significant elevation in whole brain KYNA concentrations 
in infected mice or in L-kynurenine-treated mice at the time of PPI testing, although 
KYNA levels might have been increased in specific brain regions. Given the persistent 
effects of neonatally administered NMDA receptor antagonists, e.g. PCP or MK-801, 
on sensorimotor gating in rats (Wang et al., 2001; Harris et al., 2003) it is tempting to 
suggest that also the transient elevation of KYNA in early life might have contributed 
to the deficits in PPI observed in the adult Tap1-/- and L-kynurenine-treated mice. 
Notably though, the neonatal virus infection induced similar transient increases in brain 
KYNA in wild-type as in Tap1-/- mice. The discrepancy in PPI response between these 
genotypes may reflect a general behavioural vulnerability of Tap1-/- mice due to their 
reduced expression of MHC class I molecules, which are suggested to be of importance 
for synaptic plasticity and regeneration (Oliveira et al., 2004; Goddard et al., 2007). 
Also, Tap1-/- mice showed a more persistent induction of the kynurenine pathway in 
Figure 8. (A) PPI and (B) startle magnitude during the varied ISI block of the startle 
session in 3-4-months-old mice, neonatally injected with L-kynurenine (2 x 200 
mg/kg/day, n = 8) or saline at P7-16 (n = 10). Statistical analysis was performed using a 
one-factor ANOVA, followed by a Tukey’s post hoc multiple comparison test. F(4,64) 
= 3.37, p < 0.05, interaction between L-kynurenine treatment and ISI. ** p < 0.01, 
statistically different from saline control mice. Data are presented as mean + SEM. 
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early life compared with the wild-type mice. In consonance, compared with the virus-
infection in wild-type mice, the L-kynurenine treatment is likely to result in a more 
stable and prolonged increase in brain KYNA concentration in early life. The data on 
PPI in the neonatal L-kynurenine-treated mice should be interpreted with caution, 
however, since the only statistically significant decrease in PPI was observed at the 500 
ms ISI, without a main effect on L-kynurenine treatment. 
 
 
4.1.3.2 Locomotor activity  
An open field arena was used to assess spontaneous and D-amphetamine-induced 
locomotor activity in adult life of neonatally virus-infected wild-type mice and 
neonatally L-kynurenine-treated mice, and their respective controls (paper III). 
 
Evaluation of spontaneous horizontal activity in adult wild-type mice did not reveal any 
differences between influenza virus-infected mice and their uninfected controls (Figure 
9A). Acute administration of D-amphetamine was associated with an increased 
horizontal activity in both virus-infected and uninfected control mice. However, in the 
virus-infected mice, a potentiated D-amphetamine-induced increase in horizontal 
activity was observed compared with the uninfected controls, as obtained during the 
10-50 minutes of the test period (Mann Whitney U test, p = 0.04, Figure 9B). 
 
 
Figure 9A. Horizontal activity during habituation three and following acutely administered  
D-amphetamine (5 mg/kg) or vehicle to 5-6-month-old mice, injected with influenza A virus (2,400 
plaque-forming units) or phosphate buffered saline (PBS) at P3 or P4. Each point represents the mean + 
SEM of counts recorded during five-minute intervals.  
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Figure 9B. Assessment of D-amphetamine induced increase of horizontal activity in influenza 
A/WSN/33 virus-infected (n = 8) and uninfected mice (n = 8). Bars represent mean + SEM of the 
accumulated number of counts (adjusted for baseline value, i.e. the last five min counts of habituation 
three) during 10-50 min following drug administration. Mann Whitney U test, * p < 0.05. 
 
To investigate if this behavioral aberration in infected mice is related to the elevated 
brain KYNA in early life as observed in the infected animals, the adult L-kynurenine-
treated mice were evaluated accordingly. The spontaneous horizontal activity in these 
mice did not differ from their respective saline controls (Figure 10A). A trend towards 
a potentiatiated D-amphetamine-induced increase in horizontal activity was observed in 
these mice. Unfortunately, this experiment included too few animals to achieve 
statistical significance (Figure 10B). Additional experiments are needed to confirm 
whether neonatal brain KYNA has a substantial effect on mice behavior in adult life.   
 
 
Figure 10A. Horizontal activity during habituation three and following acutely administered  
D-amphetamine (5 mg/kg) or vehicle to 3-4-month-old-mice, injected with L-kynurenine (2 x 200 
mg/kg/day) or saline at P7-16. Each point represents the mean + SEM of counts recorded during five-
minute intervals. 
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Figure 10B. Assessment of D-amphetamine induced increase of horizontal activity in L-kynurenine-
treated mice (n = 4) and saline controls (n = 5). Bars represent mean + SEM of the accumulated number 
of counts (adjusted for baseline value, i.e. the last five min counts of habituation three) during 10-50 min 
following drug administration. Mann Whitney U test, p = 0.41. 
 
 
Subchronic elevation of brain KYNA in adult rodents, possibly mimicking a 
physiological condition of patients with psychiatric disorders (Erhardt et al., 2001b; 
Linderholm et al., 2010; Olsson et al., 2010), has previously been shown to potentiate 
the D-amphetamine-induced increase in brain dopamine efflux (Olsson et al., 2009) as 
well as to exaggerate D-amphetamine-induced hyperlocomotion (Olsson et al., 2011). 
Present results are in line with the D-amphetamine-enhancement of striatal dopamine 
release observed in brain imaging studies in patients with schizophrenia (see section 
1.5.1.2), although no significant elevation in brain KYNA concentration was found at 
the time of locomotor assessments in either infected or L-kynurenine-treated mice. A 
temporary elevation of brain KYNA in neonatal life could be associated with structural 
changes in the brain as a result of dysfunctions in the glutamatergic/ 
dopaminergic/cholinergic neurotransmission during a critical period of the 
neurodevelopment. Such a view is concomitant with the theory that an early-life 
NMDA receptor hypofunction may cause irreversible morphological changes in the 
developing brain (Olney and Farber, 1995). 
 
In summary, the present behavioral studies show that a neonatal infection with the 
neurotropic influenza A/WSN/33 virus is associated with disturbances in adult wild-
type mice as reflected by increased sensitivity to D-amphetamine-induced increase in 
locomotor activity. Adult mice subjected to a subchronic elevation of endogenous brain 
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KYNA in early life showed a similar trend of hyper-responsiveness to D-amphetamine. 
Although no long-term effects of the neonatal CNS infection were observed in wild-type 
mice when tested for PPI in adult life, such deficiencies were observed in the 
genetically immunodeficient mice. Furthermore, pharmacologically elevated brain 
KYNA in early life tended to affect sensorimotor gating in adulthood. These results 
indicate that induction of the kynurenine pathway, including a transient accumulation 
of brain KYNA in early life, could contribute to behavioral deficits related to 
schizophrenia in adulthood. Thus, elevated levels of brain KYNA during a critical 
period in neurodevelopment might offer a molecular basis of infection as a risk factor 
for schizophrenia. 
 
 
4.2 HUMAN GENETIC STUDIES 
As a large body of evidence depicts a genetic involvement in the etiology of 
schizophrenia (see section 1.2.2), the last studies presented in this thesis address genetic 
aspects on the kynurenine pathway and psychotic disorders. During the past decade, the 
kynurenine pathway metabolite KYNA has gained increased attention as a potential 
keystone in dopamine-related psychiatric disorders, including schizophrenia and 
bipolar disorder (Erhardt et al., 2001a; Schwarcz et al., 2001; Nilsson et al., 2005; 
Linderholm et al., 2010; Olsson et al., 2010; Sathyasaikumar et al., 2010). Since the 
availability of kynurenine appears to be a limiting component for KYNA synthesis 
(Moroni, 1999), the formation of this end product indirectly depends on the activity of 
KMO, the enzyme converting kynurenine into 3-HK (Moroni, 1999) (Figure 1). 
Accordingly, a pharmacological inhibition of KMO, e.g. by PNU 156561A or m-
nitrobenzoyl-alanine (mNBA), will shunt the metabolism of kynurenine towards 
KYNA (Carpenedo et al., 1994; Speciale et al., 1996; Wu et al., 2000). A functional 
polymorphism of the gene encoding KMO, resulting in a reduction of its gene 
expression and/or enzyme activity, might thus participate in the elevation of KYNA 
concentration in the CSF and in the post mortem brains of patients with schizophrenia. 
In the studies presented here we analyze a possible association between KMO gene 
variations and broad-spectrum schizophrenia (including schizoaffective and 
schizophreniform disorders) in a combined case-control sample from the Scandinavian 
population (paper IV). Furthermore, CSF KYNA concentrations in a subset of the 
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Swedish population of patients with schizophrenia and healthy controls were analyzed 
with respect to KMO gene variation (paper V). In both studies, polymorphisms in 
KMO were assessed by analyzing 15 SNPs, covering at least 79% of the total variation. 
 
In the first study of the combined Scandinavian sample, no single marker (Table 3) or 
haplotype (data not shown) was associated with the disease. One SNP, rs2065799, 
showed evidence of association heterogeneity with respect to country of origin (Table 
3): The minor allele was over-represented among Norwegian patients (p = 0.01; odds 
ratio (OR) = 2.3, 95% confidence interval (CI95) 1.2 - 4.4), but no association was 
found in the Danish or Swedish samples (p-values = 0.66 and 0.16, respectively). After 
adjustment for multiple testing, the association between the marker rs2065799 and the 
disease in the Norwegian sample did not reach the threshold for global significance (p = 
0.14). No population stratification was evident between the healthy controls (FST = 
0.001 ± 0.001; 95% bootstrap confidence interval). The combined Scandinavian sample 
was well-powered to detect nominally significant allele differences of modest effects; 
for an allele OR = 1.4 the power varied between 1 and 0.72 (minor allele frequency 
[MAF] = 0.2 and MAF = 0.05, respectively). However, the power to detect an OR of 
1.2 was limited for alleles with a MAF of 0.1 or lower (power < 0.45). The present 
results are in line with a previous report of a Japanese population (Aoyama et al., 
2006), which could indicate worldwide population consensus. 
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Table 3. Allele and genotype association between SNPs in KMO and schizophrenia. 
      HWc   Case/Ctrl   Test of association (p-value) 
SNP Base(1/2)a MAFb  (p-value)   1 1 1 2 2 2   Allele  Countryd   Genotype Countryd 
RS10926508 A/G 0.03 0.30  785/1393 50/77 0/2  0.85 0.80  0.68 0.73 
RS2992642 A/C 0.26 0.89  421/773 311/537 61/95  0.15 0.72  0.35 0.80 
RS3014572 T/C 0.27 0.39  419/774 350/595 64/101  0.17 0.81  0.39 0.71 
RS2050513 C/A 0.16 0.18  598/1036 213/381 22/45  0.32 0.83  0.59 0.85 
RS3014569 T/C 0.14 1.00  620/1090 199/341 11/26  0.94 0.47  0.77 0.71 
RS10926513 A/T 0.40 0.78  307/529 392/707 137/228  0.95 0.29  0.69 0.30 
RS6661244 C/T 0.33 1.00  375/666 367/648 94/158  0.54 0.36  0.82 0.57 
RS6689793 G/C 0.09 0.15  687/1222 140/234 8/17  0.95 0.68  0.88 0.88 
RS3007737 C/T 0.43 0.46  255/486 432/704 147/277  0.58 0.76  0.23 0.69 
RS2065799 C/T 0.07 0.13  713/1268 116/193 6/12  0.66 0.04*  0.49 0.03* 
RS3765806 C/G 0.33 0.28  372/680 376/627 85/164  0.72 0.98  0.53 0.98 
RS12139441 A/G 0.18 0.42  564/998 244/421 26/51  0.95 0.52  0.83 0.52 
RS4660103 G/A 0.28 0.56  432/769 336/597 67/106  0.86 0.88  0.78 0.97 
RS850678 A/T 0.25 0.37  453/829 327/541 53/100  0.52 0.25  0.49 0.49 
RS1053230 C/T 0.23 0.46   520/873 281/528 34/71   0.23 0.45   0.48 0.43 
a Major/Minor allele 
b Minor allele frequency in controls 
c Test of Hardy-Weinberg equilibrium 
d Test of association heterogeneity 
* Indicate nominal significance (p < 0.05) 
In the second study, we found an association between the KMO polymorphism 
rs1053230 and KYNA concentrations in CSF (Likelihood ratio chi square = 10.0, df = 
1, p = 0.0015). The additive value was 1.1 (95% confidence interval between 0.34 and 
1.79) and a copy of the T-allele was associated with a 45% increase in KYNA CSF 
concentrations (least square mean for individuals with the CC and CT genotypes were 
1.0 nM, and 1.49 nM, respectively; Figure 11). The association was found in both 
patients and controls and was significant after correction for multiple testing (adjusted p 
= 0.023, empirical 5% quantile = 0.003). Although there was a tendency towards a 
stronger association in affected individuals, this difference was not statistically 
significant (p-value for affection state as modifier was 0.73). The rs1053230 is located 
on exon 15 and results in a shift of the amino acid sequence from arginine to cysteine. 
These results indicate that the different alleles of the KMO polymorphism rs1053230 
predict KYNA concentrations. At the time of CSF collection, all patients with 
schizophrenia received or had previously received antipsychotics. Such drugs have 
been reported to decrease KYNA content in the rat brain (Ceresoli-Borroni et al., 
2006), thereby limiting the functional consequence of the KMO (rs1053230) T allele.  
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This is the first study showing an association between a KMO polymorphism and a 
proposed phenotype for schizophrenia, i.e. elevated levels of CSF KYNA 
concentrations. The KMO enzyme is located on the outer membrane of mitochondria 
(Okamoto et al., 1967). According to computerized protein structure predictions, large 
parts of the protein are located inside the membrane (www.predictprotein.org). 
Interestingly, in this prediction, the KMO polymorphism rs1053230 is located in the 
part of the gene sequence coding for protein positions outside of the mitochondria 
membrane, likely to be the site for substrate interaction. An exchange of amino acids in 
this part of the enzyme may also influence substrate binding, for example by changeing 
the hydropathy index from -4.5 (arginine, the most hydrophilic amino acid) to 2.5 
(cysteine, a moderate hydrophobic amino acid) (Kyte and Doolittle, 1982). The 
increased levels of KYNA, seen in individuals with the mutant T allele, may thus 
reflect a reduction of kynurenine binding to KMO. The metabolism of kynurenine 
would thereby be shunted towards KYNA, in analogy with administration of 
pharmacological compounds blocking KMO.  
 
Figure 11. The CSF concentrations of KYNA increase with the T-allele of 
rs1053230 (p = 0.023 after correction for multiple testing). Least square 
means and standard errors are given for control and patients with 
schizophrenia with the CC, CT and TT genotypes, respectively, adjusting for 
effects of back length, age and sex. 
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Similar disease frequencies in carriers and non-carriers of the rs1053230 mutant allele 
suggest that elevated KYNA concentrations in patients suffering from schizophrenia 
(Erhardt et al., 2001a; Schwarcz et al., 2001; Nilsson et al., 2005) are more likely to 
reflect the pathophysiology of the disease than to represent a mechanism of disease 
susceptibility. It should be noted that the participants in the CSF study represent a small 
fraction of patients and control subjects (included in the previously published report 
Nilsson et al., 2005). The lack of a difference in CSF KYNA concentrations between 
patients and controls presented in our study is thus possibly related to the restricted 
number of samples analyzed. It is of interest to note that, despite this limitation, the 
KMO (rs1053230) T allele association with an increase in KYNA concentration tended 
to be stronger in patients with schizophrenia compared with healthy controls. This 
might reflect an up-regulated turnover of the kynurenine pathway in patients with 
schizophrenia. Indeed, previous studies have shown that levels of kynurenine, the 
precursor of KYNA, are increased in patients with schizophrenia (Linderholm et al., 
2010). Thus, a change in the KMO codon sequence from arginine to cysteine in 
combination with increased kynurenine turnover may predispose for elevated KYNA 
levels as seen in patients with schizophrenia.  
 
In summary, the present association studies analyzing genetic variations in the KMO 
gene reveal that increased levels of CSF KYNA, as previously reported in patients with 
schizophrenia, are associated with a functional missense polymorphism in the KMO 
gene. However, the KMO gene polymorphisms investigated are not likely to confer 
major susceptibility to schizophrenia per se. 
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5 GENERAL DISCUSSION 
Accumulating evidence suggests that schizophrenia is associated with immunological 
processes in the brain. Direct evidence for a central immune activation is relatively 
sparse, and conceivably, the most prominent studies in this regard show elevated levels 
of IL-1β and IL-6 (Garver et al., 2003; Söderlund et al., 2009; Schwieler et al., 2011) as 
well as KYNA in the CNS of affected patients (Erhardt et al., 2001a; Schwarcz et al., 
2001; Nilsson et al., 2005; Linderholm et al., 2010; Sathyasaikumar et al., 2010). 
Indeed, not only cytokines, but also kynurenine pathway metabolites are suggested as 
regulatory mediators of the innate and adaptive immune responses, reviewed in (King 
and Thomas, 2007; Gonzalez et al., 2008). Recent results from our laboratory show that 
IL-1β induces genes encoding the enzymes IDO and TDO, resulting in increased 
concentration of KYNA (Kegel et al., 2011). These findings may link together the 
elevation of IL-1β, KYNA and TDO activity seen in the CNS of patients with 
schizophrenia into a common pathophysiological assembly underlying the disease 
(Erhardt et al., 2001a; Schwarcz et al., 2001; Nilsson et al., 2005; Miller et al., 2006; 
Söderlund et al., 2009; Linderholm et al., 2010; Sathyasaikumar et al., 2010). Further 
support for an immunological involvement in schizophrenia is presented by the finding 
of mRNA sequences of the human endogenous retrovirus (HERV) in the CSF of 
affected patients (Karlsson et al., 2001). Also, increased mRNA expression of genes 
related to various immune responses has been found in the brain of patients with 
schizophrenia (Saetre et al., 2007). Clearly, infection, particularly in early-life is 
considered a risk factor for development of the disease. Thus, early-life exposure to a 
variety of infectious pathogens, such as Toxoplasma gondii, mumps virus, rubella virus, 
HSV type 2, cytomegalovirus and influenza viruses, is associated with development of 
psychotic illness, including schizophrenia (Brown et al., 2000a; Buka et al., 2001a; 
Mortensen et al., 2007; Dalman et al., 2008). However, since no specific infectious 
agent appears responsible for the development of schizophrenia, this implies a common 
mechanism of immune activation in the disease, possibly including an abnormal 
expression of specific cytokines in early brain development (Meyer et al., 2009). 
Indeed, cytokines are also suggested to influence neurodevelopment (Bauer et al., 
2007; Deverman and Patterson, 2009), and could underlie abnormal 
cytoarchitectonics of the brain as postulated by the neurodevelopmental hypothesis of 
schizophrenia, reviewed in (Marenco and Weinberger, 2000). The findings of the 
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present thesis show that a neonatal virus infection is associated with an early-life 
induction of the kynurenine pathway and with schizophrenia-like behavior in the adult 
mouse, hereby merging together the neurodevelopmental hypothesis of schizophrenia 
with the view of an immune activation in the disease.  
 
 
In addition to an immune-mediated induction of the kynurenine pathway, impairments 
of the KMO enzyme might contribute to the increased KYNA concentration observed 
in patients with schizophrenia. KMO converts kynurenine to 3-HK and experimental 
studies show that pharmacological inhibition of this enzyme leads to increased brain 
KYNA concentration (Speciale et al., 1996). In the present thesis, an association was 
found between the non-synonymous missense KMO SNP rs1053230 (changing the 
amino acid codon) and CSF KYNA concentration. Given the position of the SNP in the 
gene region, this genetic variation is likely to affect the interaction between the KMO 
enzyme and its substrate kynurenine. Thus, this SNP seems particularly relevant for 
kynurenine metabolism. It was recently shown that KMO gene expression as well as the 
enzyme activity is down-regulated in the post mortem brain of patients with 
schizophrenia (Wonodi et al., 2011). In that study, another KMO SNP (rs2275163) was 
associated with neurocognitive endophenotypic deficits (Wonodi et al., 2011). Overall, 
these findings support a malfunctioning KMO enzyme in schizophrenia. Interestingly, 
the presently shown association between the minor (T) allele of the KMO SNP 
rs1053230 and increased CSF KYNA concentrations tended to be stronger in patients 
with schizophrenia, suggesting that the activity of up-stream enzymes in the kynurenine 
pathway (i.e. IDO or TDO) is concomitantly increased. Kynurenine concentration is 
indeed elevated in the brain and the CSF of patients with schizophrenia (Linderholm et 
al., 2010; Sathyasaikumar et al., 2010), and the kynurenine availability is shown to be 
essential for the production of KYNA (Moroni, 1999). Notably, the KMO gene maps to 
the chromosome region 1q42-q44, a block that shows a strong linkage to schizophrenia 
(Owen et al., 2004) making analysis of this gene particularly relevant for the disease 
etiology. In line with a Japanese study (Aoyama et al., 2006) we could not report a 
schizophrenia association with any KMO SNP investigated. However, in both our and 
the Japanese study, an initial association was found. Thus, in the Norwegian 
population, the KMO SNP rs1053230 was nominally associated with schizophrenia. In 
this aspect, the strategy of analyzing possible associations with phenotypes, such as 
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CSF KYNA, rather than the disease per se, is probably a more constructive genetic 
approach for complex diseases like schizophrenia, as reviewed in (Meyer-Lindenberg 
and Weinberger, 2006).  
 
The present thesis, comprising studies both in vitro and in vivo, depicts a prominent 
effect of the neurotropic influenza A/WSN/33 virus in activating the kynurenine 
pathway, as revealed by the transcript induction of enzymes along the pathway and by 
elevated levels of KYNA. This is in line with clinical findings showing that infections 
trigger the kynurenine pathway, as reflected by elevated concentrations of various 
kynurenine metabolites, including for example KYNA and QUIN, in the CSF or brain 
of patients with cerebral infections such as HIV-1, TBE and cerebral malaria as well as 
other CNS inflammatory neurological diseases (Heyes et al., 1992b; Medana et al., 
2002; Atlas et al., 2007; Holtze et al., 2011). Indeed, several metabolites of the 
kynurenine pathway have immunomodulatory functions, and may be implicated in the 
host defense of invading pathogens.  Thus, although metabolites such as 3-HK and 
QUIN were not measured in the present thesis, elevated transcript levels of KMO, 
KYNU, HAAO and QPRT indicate that the synthesis of these metabolites is increased. 
One might speculate that exposure to infections in early life results in elevated levels of 
various kynurenine pathway metabolites that all contribute to a disturbed immune 
balance in the developing brain. However, the physiological consequences of elevated 
levels of these metabolites are ambiguous since elevated levels of KYNA are shown to 
dampen the effects of some of these compounds. Thus, KYNA is able to scavenge free 
radicals generated by 3-HK (Goda et al., 1999; Lugo-Huitron et al., 2011). With regard 
to QUIN, a large body of evidence shows that KYNA blocks the excitotoxic effects of 
this NMDA receptor agonist (Foster et al., 1984; Sas et al., 2007). Furthermore, 
endogenous KYNA has been demonstrated to control the vulnerability to QUIN 
neurotoxicity in the mouse brain (Sapko et al., 2006), and a reduced concentration of 
KYNA is required for a toxic effect of QUIN.  
 
In the present thesis, neonatal infection with a neurotropic strain of influenza A virus 
increased brain KYNA concentrations in both wild-type mice and in immunodeficient 
Tap1−/− mice. Interestingly, the neonatal infection was associated with deficits in PPI in 
the adult immunodeficient mice and a hyper-responsiveness to D-amphetamine in 
locomotor response in the adult wild-type mice. To investigate if the elevated levels 
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of endogenous KYNA seen in the infected neonatal mice could account for the 
observed long-lasting behavioral disturbances, we investigated behavioral effects in 
adult mice neonatally treated with L-kynurenine, the BBB-crossing precursor of 
KYNA. Indeed, pharmacologically elevated levels of endogenous brain KYNA in 
neonatal mice tended to result in a hyper-responsiveness to D-amphetamine, and was 
associated with mild reductions in PPI in adulthood. These results are in line with 
brain imaging studies in patients with schizophrenia reporting an enhanced striatal 
dopamine release by D-amphetamine (Laruelle et al., 1996; Breier et al., 1997; Abi-
Dargham et al., 1998; Laruelle and Abi-Dargham, 1999), and the frequently observed 
PPI deficits in these patients (Braff et al., 2001). Kynurenine is preferentially 
metabolized to 3-HK under normal physiological conditions. However, with regard to 
the biochemical kinetics of KMO and KYNU, these enzymes should be saturated more 
rapidly at rising kynurenine concentrations than the KAT enzymes. Therefore, 
synthesis of KYNA ought to be favored when L-kynurenine is systemically 
administered. Indeed, focal infusion of 3H-kynurenine in the rat brain has been shown 
to increase KYNA to a higher extent than QUIN, with a ratio of 1 to 0.2 (Guidetti et al., 
1995; Amori et al., 2009). In all probability the effects of systemically administered  
L-kynurenine in the present study are related to increased levels of brain KYNA rather 
than any other kynurenine pathway metabolite. Thus, as the neonatal virus-infection 
and the neonatal L-kynurenine-treatment showed similar behavioral aberrations, the 
long-term effects of the neonatal virus infection may specifically be related to the 
increase in endogenous brain KYNA concentration. 
 
The findings of the present studies are in line with the neurodevelopmental hypothesis 
of schizophrenia, suggesting early life as a particularly vulnerable time for 
environmental insults (Olney et al., 1999; Marenco and Weinberger, 2000). Indeed, 
administration of NMDA receptor antagonists during a critical period of brain 
development has been shown to result in apoptotic neurodegeneration (Rudin et al., 
2005; Young et al., 2005; Ikonomidou, 2009), as well as in persistent behavioral 
deficits in rodents (Harris et al., 2003; Fredriksson et al., 2007; Mouri et al., 2007). In 
addition, the α7nACh receptor has been implicated in neurodevelopmental processes 
(Ross et al., 2010). Interestingly, long-term behavioral effects of elevated brain KYNA 
are also implied in two recent studies were a subchronic elevation of brain KYNA 
concentration during adolescence was associated with cognitive dysfunctions as well as 
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decreased social interaction in the young adult rat (Akagbosu et al., 2010; Trecartin and 
Bucci, 2011). Given the unique receptor-binding profile of KYNA, present findings 
further emphasize a significant role of KYNA as a mediator of the behavioral 
alterations observed in adult mice. A temporary elevation of brain KYNA in neonatal 
life could be associated with persistent dysfunctions in glutamatergic/cholinergic/ 
dopaminergic neurotransmission, hereby affecting neuronal circuits that are important 
for brain development. Alternatively, an increased turnover in brain KYNA may be 
long-lasting and persist throughout the time period for behavioral evaluation. In this 
regard, it is notable that the neonatal influenza virus-infection in both 
immunodeficient Tap1-/- and wild-type mice, as well as the neonatal L-kynurenine 
treatment, tended to be associated with a small increase in whole brain KYNA 
content in adult life, hereby indicating a persistently increased turnover of brain 
KYNA (Table 2: Infected Tap1-/- 1.4-fold increase, infected wild-type 1.2-fold 
increase, L-kynurenine-treated 1.3-fold increase). This is in line with a recent 
microdialysis study showing increased extracellular KYNA levels in adulthood 
following perinatal treatment with L-kynurenine (Pocivavsek et al., 2011a). Indeed, 
subchronic elevation of brain KYNA in adult rodents, mimicking a 
pathophysiological condition in patients with psychotic disorders, has been shown to 
potentiate the D-amphetamine-induced increase in brain dopamine efflux and in 
locomotor activity (Olsson et al., 2009; Olsson et al., 2011). Furthermore, acutely 
increased brain KYNA in rats is associated with impaired sensorimotor gating 
(Erhardt et al., 2004). Thus, a slight but long-lasting increase in KYNA turnover 
might, by itself or in symphony with neurodevelopmental effects, contribute to the 
presently observed behavioral aberrations in adult life.  
 
The results of the present thesis, derived from both experimental studies and genetic 
association studies, offer substantial support to the view that KYNA participates in 
the etiology of schizophrenia. During the past few years it has become increasingly 
evident that this tryptophan-derived neuroactive metabolite serves as a biomarker of 
immune activation in the brain. The complicated interplay between the kynurenine 
pathway and the more traditional mediators of the immune system, e.g. cytokines and 
prostaglandins, is a venue for future investigations. For example, not only are 
cytokines able to induce the kynurenine pathway, but also kynurenine metabolites are 
shown to induce cytokine release (Guillemin et al., 2003a; Wang et al., 2006; Fallarini 
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et al., 2010; Kegel et al., 2010). Moreover, although the kynurenine pathway is the 
major route of KYNA production, another pathway for the synthesis of KYNA has 
been suggested: a stress-induced oxidative pathway mediated though indol-3-pyruvic 
acid (Bartolini et al., 2003). Investigations of this pathway with regard to immune 
activation and behavioral abnormalities as well as genetic variations might offer 
additional insight into the pathophysiology/etiology of schizophrenia.   
 
In summary, the present thesis shows that a neurotropic virus infection in early life is 
associated with an induction of the kynurenine pathway followed by behavioral 
aberrations in the adult mouse, and that a genetic deficit in this pathway is associated 
with increased CSF KYNA in patients with schizophrenia and in healthy controls. 
Indeed, a genetic disturbance in patients with schizophrenia is essentially what was 
proposed in the initial neurodevelopmental hypothesis of this disease. However, it has 
become increasingly apparent that genetic aberrations only partly contribute to the 
etiology of this disease. In this regard, an early-life exposure to infection could have a 
more substantial effect on an already genetically vulnerable neuronal system (Cannon 
et al., 2003). This view is in line with our findings of a more pronounced induction of 
the kynurenine pathway in early life in the immunodeficient Tap1-/- mice. Hereby, our 
results further support a gene-environmental interaction as suggested in the 
development of schizophrenia. Thus, a genetic deficit of the KMO gene concomitantly 
with an immune-mediated induction of IDO or TDO activity should trigger the 
production of brain KYNA as observed in patients with schizophrenia. Altogether, this 
thesis suggests that an early-life CNS induction and/or a genetic deficit of the 
kynurenine pathway could predispose for development of schizophrenia through the 
elevation of brain KYNA.  
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